US20060182821A1 - Use of a plant extract - Google Patents
Use of a plant extract Download PDFInfo
- Publication number
- US20060182821A1 US20060182821A1 US11/405,392 US40539206A US2006182821A1 US 20060182821 A1 US20060182821 A1 US 20060182821A1 US 40539206 A US40539206 A US 40539206A US 2006182821 A1 US2006182821 A1 US 2006182821A1
- Authority
- US
- United States
- Prior art keywords
- cells
- expression
- patient
- cancer cells
- egb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000419 plant extract Substances 0.000 title 1
- 101710166801 Translocator protein Proteins 0.000 claims abstract description 111
- 102100031274 Translocator protein Human genes 0.000 claims abstract description 107
- SQOJOAFXDQDRGF-MMQTXUMRSA-N ginkgolide-b Chemical compound O[C@H]([C@]12[C@H](C(C)(C)C)C[C@H]3OC4=O)C(=O)O[C@H]2O[C@]24[C@@]13[C@@H](O)[C@@H]1OC(=O)[C@@H](C)[C@]21O SQOJOAFXDQDRGF-MMQTXUMRSA-N 0.000 claims abstract description 94
- SQOJOAFXDQDRGF-WJHVHIKBSA-N ginkgolide B Natural products O=C1[C@@H](C)[C@@]2(O)[C@@H]([C@H](O)[C@]34[C@@H]5OC(=O)[C@]23O[C@H]2OC(=O)[C@H](O)[C@@]42[C@H](C(C)(C)C)C5)O1 SQOJOAFXDQDRGF-WJHVHIKBSA-N 0.000 claims abstract description 93
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 88
- 230000014509 gene expression Effects 0.000 claims abstract description 84
- 238000000034 method Methods 0.000 claims abstract description 71
- 201000011510 cancer Diseases 0.000 claims abstract description 47
- 230000003247 decreasing effect Effects 0.000 claims abstract description 42
- 230000035755 proliferation Effects 0.000 claims abstract description 30
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 20
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 20
- 210000004027 cell Anatomy 0.000 claims description 149
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims description 32
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108020004999 messenger RNA Proteins 0.000 claims description 16
- 210000004881 tumor cell Anatomy 0.000 claims description 16
- 230000001105 regulatory effect Effects 0.000 claims description 13
- 102000006495 integrins Human genes 0.000 claims description 12
- 108010044426 integrins Proteins 0.000 claims description 12
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 claims description 11
- 101150111584 RHOA gene Proteins 0.000 claims description 11
- 108700020796 Oncogene Proteins 0.000 claims description 9
- 230000002018 overexpression Effects 0.000 claims description 9
- 101800001622 120 kDa surface-exposed protein Proteins 0.000 claims description 8
- 102000003780 Clusterin Human genes 0.000 claims description 8
- 108090000197 Clusterin Proteins 0.000 claims description 8
- 102000043276 Oncogene Human genes 0.000 claims description 8
- 102100022407 Probable 28S rRNA (cytosine(4447)-C(5))-methyltransferase Human genes 0.000 claims description 8
- 102000015735 Beta-catenin Human genes 0.000 claims description 7
- 108060000903 Beta-catenin Proteins 0.000 claims description 7
- 108050006400 Cyclin Proteins 0.000 claims description 7
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 claims description 7
- 108700036622 ETS translocation variant 3 Proteins 0.000 claims description 7
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 claims description 7
- 101150098203 grb2 gene Proteins 0.000 claims description 7
- 102100038099 Cell division cycle protein 20 homolog Human genes 0.000 claims description 6
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 claims description 6
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 claims description 6
- 101000927793 Homo sapiens Neuroepithelial cell-transforming gene 1 protein Proteins 0.000 claims description 6
- 101001124937 Homo sapiens Pre-mRNA-splicing factor 38B Proteins 0.000 claims description 6
- 101000640876 Homo sapiens Retinoic acid receptor RXR-beta Proteins 0.000 claims description 6
- 101000631937 Homo sapiens Sodium- and chloride-dependent glycine transporter 2 Proteins 0.000 claims description 6
- 101000639975 Homo sapiens Sodium-dependent noradrenaline transporter Proteins 0.000 claims description 6
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 claims description 6
- 102000002746 Inhibins Human genes 0.000 claims description 6
- 108010004250 Inhibins Proteins 0.000 claims description 6
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 claims description 6
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims description 6
- 102100034253 Retinoic acid receptor RXR-beta Human genes 0.000 claims description 6
- 102100023132 Transcription factor Jun Human genes 0.000 claims description 6
- 239000000893 inhibin Substances 0.000 claims description 6
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 5
- 101710109611 Cell division cycle protein 20 homolog Proteins 0.000 claims description 5
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims description 5
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 claims description 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 5
- 101150111463 ID2 gene Proteins 0.000 claims description 5
- 102100037925 Prothymosin alpha Human genes 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 102000049853 macrophage stimulating protein Human genes 0.000 claims description 5
- 108010053292 macrophage stimulating protein Proteins 0.000 claims description 5
- 108010014750 prothymosin alpha Proteins 0.000 claims description 5
- KMXPHBJUGYLXDM-LSDHHAIUSA-N 1-[(7r,8s)-7-hydroxy-6,6-dimethyl-7,8-dihydropyrano[2,3-f][2,1,3]benzoxadiazol-8-yl]piperidin-2-one Chemical compound N1([C@H]2C3=CC4=NON=C4C=C3OC([C@@H]2O)(C)C)CCCCC1=O KMXPHBJUGYLXDM-LSDHHAIUSA-N 0.000 claims description 4
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims description 4
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims description 4
- 101000850748 Homo sapiens Tumor necrosis factor receptor type 1-associated DEATH domain protein Proteins 0.000 claims description 4
- 108090000973 Myeloblastin Proteins 0.000 claims description 4
- 102100034681 Myeloblastin Human genes 0.000 claims description 4
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 claims description 4
- 101100225582 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nip-1 gene Proteins 0.000 claims description 4
- 102100033081 Tumor necrosis factor receptor type 1-associated DEATH domain protein Human genes 0.000 claims description 4
- 230000003831 deregulation Effects 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 102100026445 A-kinase anchor protein 17A Human genes 0.000 claims description 3
- 108010085277 Adenosine A2A receptor Proteins 0.000 claims description 3
- 102000007471 Adenosine A2A receptor Human genes 0.000 claims description 3
- 206010003571 Astrocytoma Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 102000005720 Glutathione transferase Human genes 0.000 claims description 3
- 108010070675 Glutathione transferase Proteins 0.000 claims description 3
- 101000718019 Homo sapiens A-kinase anchor protein 17A Proteins 0.000 claims description 3
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims description 3
- 101710127797 Macrophage colony-stimulating factor 1 Proteins 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 201000010897 colon adenocarcinoma Diseases 0.000 claims description 3
- 108700024542 myc Genes Proteins 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims 2
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 claims 1
- 102000018710 Heparin-binding EGF-like Growth Factor Human genes 0.000 claims 1
- 102000055056 N-Myc Proto-Oncogene Human genes 0.000 claims 1
- 102100029436 Pre-mRNA-splicing factor 38B Human genes 0.000 claims 1
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 claims 1
- 235000008100 Ginkgo biloba Nutrition 0.000 abstract description 21
- 239000000284 extract Substances 0.000 abstract description 19
- 244000194101 Ginkgo biloba Species 0.000 abstract description 17
- 230000009702 cancer cell proliferation Effects 0.000 abstract description 5
- 230000004663 cell proliferation Effects 0.000 description 50
- 230000000694 effects Effects 0.000 description 33
- 238000011282 treatment Methods 0.000 description 31
- 241001465754 Metazoa Species 0.000 description 21
- 239000003446 ligand Substances 0.000 description 21
- 239000000203 mixture Substances 0.000 description 19
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 17
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 17
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 16
- 230000027455 binding Effects 0.000 description 15
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 238000012744 immunostaining Methods 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 150000003431 steroids Chemical class 0.000 description 9
- -1 terpene lactones Chemical class 0.000 description 9
- 150000003505 terpenes Chemical class 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 229930184727 ginkgolide Natural products 0.000 description 8
- 230000002062 proliferating effect Effects 0.000 description 8
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 239000009429 Ginkgo biloba extract Substances 0.000 description 7
- 102000040945 Transcription factor Human genes 0.000 description 7
- 108091023040 Transcription factor Proteins 0.000 description 7
- 229950004398 broxuridine Drugs 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 229940068052 ginkgo biloba extract Drugs 0.000 description 7
- 239000003102 growth factor Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 238000010348 incorporation Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 101150073031 cdk2 gene Proteins 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 108090000257 Cyclin E Proteins 0.000 description 5
- 102000003909 Cyclin E Human genes 0.000 description 5
- 101000845233 Homo sapiens Translocator protein Proteins 0.000 description 5
- RAVIZVQZGXBOQO-UHFFFAOYSA-N PK-11195 Chemical compound N=1C(C(=O)N(C)C(C)CC)=CC2=CC=CC=C2C=1C1=CC=CC=C1Cl RAVIZVQZGXBOQO-UHFFFAOYSA-N 0.000 description 5
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 5
- 102100028886 Sodium- and chloride-dependent glycine transporter 2 Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000024245 cell differentiation Effects 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 108091008800 n-Myc Proteins 0.000 description 5
- 238000001543 one-way ANOVA Methods 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 description 4
- 235000011201 Ginkgo Nutrition 0.000 description 4
- 241000218628 Ginkgo Species 0.000 description 4
- 208000032612 Glial tumor Diseases 0.000 description 4
- 206010018338 Glioma Diseases 0.000 description 4
- 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 description 4
- 108091054455 MAP kinase family Proteins 0.000 description 4
- 102000043136 MAP kinase family Human genes 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 210000001700 mitochondrial membrane Anatomy 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 235000007586 terpenes Nutrition 0.000 description 4
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 3
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 101001003233 Homo sapiens Immediate early response gene 2 protein Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 102100020702 Immediate early response gene 2 protein Human genes 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 230000030648 nucleus localization Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 102000016914 ras Proteins Human genes 0.000 description 3
- 238000013391 scatchard analysis Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 2
- 102000015936 AP-1 transcription factor Human genes 0.000 description 2
- 108050004195 AP-1 transcription factor Proteins 0.000 description 2
- 206010001488 Aggression Diseases 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108700002232 Immediate-Early Genes Proteins 0.000 description 2
- 102100022337 Integrin alpha-V Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108010051791 Nuclear Antigens Proteins 0.000 description 2
- 102000019040 Nuclear Antigens Human genes 0.000 description 2
- 102000007999 Nuclear Proteins Human genes 0.000 description 2
- 108010089610 Nuclear Proteins Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 101000738717 Pelophylax lessonae Prothymosin alpha Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 108010016283 TCF Transcription Factors Proteins 0.000 description 2
- 102000000479 TCF Transcription Factors Human genes 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 108010048673 Vitronectin Receptors Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 208000012761 aggressive behavior Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000000211 autoradiogram Methods 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 238000012925 biological evaluation Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000008809 cell oxidative stress Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000008094 contradictory effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 108010078931 elastase receptor Proteins 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000008556 epithelial cell proliferation Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000002710 gonadal effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 230000000365 steroidogenetic effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 238000011870 unpaired t-test Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- RZPAXNJLEKLXNO-UHFFFAOYSA-N (20R,22R)-3beta,22-Dihydroxylcholest-5-en Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C(O)CCC(C)C)C1(C)CC2 RZPAXNJLEKLXNO-UHFFFAOYSA-N 0.000 description 1
- RZPAXNJLEKLXNO-GFKLAVDKSA-N (22R)-22-hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)[C@H](O)CCC(C)C)[C@@]1(C)CC2 RZPAXNJLEKLXNO-GFKLAVDKSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- VQVUBYASAICPFU-UHFFFAOYSA-N (6'-acetyloxy-2',7'-dichloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(OC(C)=O)C=C1OC1=C2C=C(Cl)C(OC(=O)C)=C1 VQVUBYASAICPFU-UHFFFAOYSA-N 0.000 description 1
- FXEDIXLHKQINFP-UHFFFAOYSA-N 12-O-tetradecanoylphorbol-13-acetate Natural products CCCCCCCCCCCCCC(=O)OC1CC2(O)C(C=C(CO)CC3(O)C2C=C(C)C3=O)C4C(C)(C)C14OC(=O)C FXEDIXLHKQINFP-UHFFFAOYSA-N 0.000 description 1
- 101710194912 18 kDa protein Proteins 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 108020005096 28S Ribosomal RNA Proteins 0.000 description 1
- 101150066375 35 gene Proteins 0.000 description 1
- AEUAEICGCMSYCQ-UHFFFAOYSA-N 4-n-(7-chloroquinolin-1-ium-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;dihydrogen phosphate Chemical compound OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 AEUAEICGCMSYCQ-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical class CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108700021053 Basic Helix-Loop-Helix Leucine Zipper Transcription Factor Proteins 0.000 description 1
- 102000043895 Basic helix-loop-helix leucine zipper transcription factor Human genes 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101000845242 Bos taurus Translocator protein Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000004354 CD11b Antigen Human genes 0.000 description 1
- 108010017009 CD11b Antigen Proteins 0.000 description 1
- 108700020472 CDC20 Proteins 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 101150023302 Cdc20 gene Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000218631 Coniferophyta Species 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- 102100023580 Cyclic AMP-dependent transcription factor ATF-4 Human genes 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108010068192 Cyclin A Proteins 0.000 description 1
- 102000002554 Cyclin A Human genes 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000010170 Death domains Human genes 0.000 description 1
- 108050001718 Death domains Proteins 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108010039287 Diazepam Binding Inhibitor Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- 101710124086 Envelope protein UL45 Proteins 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 102100028138 F-box/WD repeat-containing protein 7 Human genes 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 1
- 101000905743 Homo sapiens Cyclic AMP-dependent transcription factor ATF-4 Proteins 0.000 description 1
- 101001060231 Homo sapiens F-box/WD repeat-containing protein 7 Proteins 0.000 description 1
- 101000979223 Homo sapiens N-terminal EF-hand calcium-binding protein 3 Proteins 0.000 description 1
- 101000589482 Homo sapiens Nuclear cap-binding protein subunit 2 Proteins 0.000 description 1
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 1
- 101000873111 Homo sapiens Vesicle transport protein SEC20 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 108010072255 Integrin alpha3beta1 Proteins 0.000 description 1
- 108010041012 Integrin alpha4 Proteins 0.000 description 1
- 102000000426 Integrin alpha6 Human genes 0.000 description 1
- 108010041100 Integrin alpha6 Proteins 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 108700041567 MDR Genes Proteins 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091057508 Myc family Proteins 0.000 description 1
- 102100023213 N-terminal EF-hand calcium-binding protein 3 Human genes 0.000 description 1
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 description 1
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 description 1
- 108010049404 Prokaryotic Initiation Factor-3 Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100010298 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pol2 gene Proteins 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 206010054880 Vascular insufficiency Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 102000004962 Voltage-dependent anion channels Human genes 0.000 description 1
- 108090001129 Voltage-dependent anion channels Proteins 0.000 description 1
- 230000004156 Wnt signaling pathway Effects 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- SQOJOAFXDQDRGF-DWAMOYEXSA-N [H]C1([H])[C@@]([H])(C(C)(C)C)C23C45[C@]1([H])OC(=O)[C@]4(O[C@]2([H])OC(=O)[C@@]3([H])O)[C@@]1(O)[C@]([H])(C)C(=O)O[C@@]1([H])[C@]5([H])O Chemical compound [H]C1([H])[C@@]([H])(C(C)(C)C)C23C45[C@]1([H])OC(=O)[C@]4(O[C@]2([H])OC(=O)[C@@]3([H])O)[C@@]1(O)[C@]([H])(C)C(=O)O[C@@]1([H])[C@]5([H])O SQOJOAFXDQDRGF-DWAMOYEXSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 208000030224 brain astrocytoma Diseases 0.000 description 1
- 201000007983 brain glioma Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 230000011496 cAMP-mediated signaling Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000001819 effect on gene Effects 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 230000008622 extracellular signaling Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000012296 in situ hybridization assay Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 108010028309 kalinin Proteins 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000002332 leydig cell Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 208000030883 malignant astrocytoma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 150000004633 phorbol derivatives Chemical class 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000035409 positive regulation of cell proliferation Effects 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960000249 pregnenolone Drugs 0.000 description 1
- OZZAYJQNMKMUSD-DMISRAGPSA-N pregnenolone succinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 OZZAYJQNMKMUSD-DMISRAGPSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004263 retinal angiogenesis Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- BTGNGJJLZOIYID-UHFFFAOYSA-N sivelestat Chemical compound C1=CC(OC(=O)C(C)(C)C)=CC=C1S(=O)(=O)NC1=CC=CC=C1C(=O)NCC(O)=O BTGNGJJLZOIYID-UHFFFAOYSA-N 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000010009 steroidogenesis Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical class CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 230000001573 trophoblastic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 208000023577 vascular insufficiency disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000001792 virilizing effect Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
Definitions
- the present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated ginkgolide B (GKB), a component of the extract of Ginkgo biloba leaves in a method for decreasing the expression of peripheral-type benzodiazepine_receptor (PBR) in cells of a patient in need thereof. Further, the present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated GKB in a method for decreasing the proliferation of cancer cells in a patient in need thereof. More particularly, the present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated GKB in a method of decreasing cancer cell proliferation in a patient in need thereof wherein said cancer cell is human breast cancer cells.
- GKB isolated ginkgolide B
- PBR peripheral-type benzodiazepine_receptor
- the present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated GKB in a method of decreasing cancer cell proliferation in a patient in need thereof wherein said cancer cell are of the aggressive and invasive phenotype and expresses high levels of PBR in comparison to non-aggressive cancer cells.
- the present invention is directed to the use of extract of Ginkgo biloba leaves to decrease the expression of thirty-five (35) gene products as is further detailed, hereinbelow.
- Ginkgo biloba leaves extract known as EGB 761® (a product of IPSEN, Paris, France) be a constituent in a composition or used in a method of the present invention.
- Ginkgo biloba is one of the most ancient trees and extracts from its leaves have been used in traditional medicine for several hundred years. There are numerous studies describing the beneficial effects of Ginkgo biloba extracts on patients with disturbances in vigilance, memory, and cognitive functions associated with aging and senility, and on those with all types of dementias, mood changes, and the ability to cope with daily stressors.
- a standardized extract of Ginkgo biloba leaves, termed EGB 761® has been used in most of these studies. This extract is also known to have cardioprotective effects (DeFeudis F. V. Ginkgo biloba extract (EGB 761®): from chemistry to clinic. Ullstein Medical, Wisbaden, Germany. 400 pp.
- EGB 761® Ginkgo biloba Extract
- the extract contains 24% ginkgo-flavone glycosides, 6% terpene lactones (ginkgolides and bilobalide), about 7% proanthocyanidins and several other constituents. See Boralle, N., et al., In: Ginkgolides, Chemistry, Biology, Pharmacology and Clinical perspectives, Ed: Braquet, P., J. R. Prous Science Publishers, 1988.
- Tumor progression is a multi-step process in which normal cells gradually acquire more malignant phenotypes, including the ability to invade tissues and form metastases, the primary cause of mortality in breast cancer.
- the “aberrant” expression of a number of gene products may be the cause or the result of tumorigenesis.
- the first step of tumor progression is cell proliferation, it can be proposed that tumorigenesis and malignancy are related to the proliferative potential of tumoral cells.
- PBR is an 18-kDa protein discovered as a class of binding sites for benzodiazepines distinct from the GABA neurotransmitter receptor (Papadopoulos, V. (1993) Endocr. Rev. 14:222-240). PBR are extremely abundant in steroidogenic cells and found primarily on outer mitochondrial membranes (Anholt, R. et al. (1986) J. Biol. Chem. 261:576-583). PBR is thought to be part of the multimeric complex composed of the 18-kDa isoquinoline-binding protein and the 34-kDa pore-forming voltage-dependent anion channel protein, preferentially located on the outer/inner mitochondrial membrane contact sites (McEnery, M. W. et al.
- peripheral-type benzodiazepine receptor is part of the changes in cellular and molecular functions that account for the increased aggressive behavior in cancer, and we chose to examine this hypothesis in human breast cancer.
- Breast cancer is the most common neoplasm and the leading cause of cancer-related deaths for women in most developing countries (Lippman, M. E. (1993) Science 259:631-632), affecting nearly 184,000 women, with over 46,000 deaths annually in the U.S. alone (American Cancer Society, 1996).
- Human breast cells are unlike brain and gonadal cells and cannot produce steroids, but like many other cells in the body, are able to metabolize steroids.
- Increased PBR expression correlates with increased aggressive behavior of tumor cells. Invasive tumors invade and grow locally but they do not metastasize. However, the aggressive tumors have the ability to invade and metastasize through the blood vessels to different places of the human body. Tumor metastasis into vital organs (such as lungs) is the most common cause of death.
- the present invention is directed to a method of combating cancer in a patient in need of such combating, wherein the cancer is caused by the deregulation of expression of proteins having a role in regulating tumor cells, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.
- the present invention is directed to a method of combating the proliferation of cancer cells in a patient in need of such combating, wherein the proliferation is caused by the deregulation of expression of proteins having a role in regulating tumor cells, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.
- the present invention is directed to a method of combating the proliferation of cancer cells in a patient in need of such combating, wherein the proliferation is caused by over-expression of proteins having a role in regulating tumor cells, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.
- the present invention is directed to a method of combating the proliferation of cancer cells having an aggressive phenotype in a patient in need of such combating, wherein the proliferation is caused by the over-expression of peripheral-type benzodiazepine receptor protein, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.
- the present invention is directed to a method of combating the proliferation of cancer cells, where the proliferation is caused by the over-expression of oncogenes, by decreasing the expression of said oncogenes in a patient in need of such combating, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.
- a preferred method of the immediately foregoing method is where said oncogenes are one or more of APC, PE-1, RhoA and c-Jun.
- the present invention is directed to a method of decreasing the expression of peripheral-type benzodiazepine receptor mRNA in cancer cells in a patient in need of such decreasing, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.
- the present invention is directed to a method of increasing the expression of c-Myc protooncogene in a patient in need of such increasing, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.
- the present invention is directed to a method of decreasing the expression of apoptosis-related proteins Adenosine A2A Receptor, Flt3 ligand, Grb2, Clusterin, RXR- ⁇ , Glutathione S-transferase P, N-Myc, TRADD, SGP-2 and NIP-1, in a patient in need of such decreasing, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.
- the present invention is directed to a method of decreasing the expression of growth factors macrophage colony-stimulating factor-1, heparin-binding EGF-like growth factor, hepatocyte growth factor-like protein and inhibin ⁇ , in a patient in need of such decreasing, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.
- Ginkgo biloba extracts is EGB 761®.
- Ginkgolide B is used.
- FIG. 2 Effect of various concentrations of GKB on MDA-231 PBR ligand binding capacity.
- MDA-231 cells were cultured as described under Materials and Methods. Cells were treated with the indicated concentrations of GKB for 48 hours. At the indicated time periods cells were then collected and PBR ligand binding characteristics were determined by Scatchard analysis. Data points represent the mean ⁇ S.D. of two independent experiments carried out in triplicate.
- FIG. 3 Effect of EGB 761® and GKB on PBR mRNA levels in MDA-231 cells.
- Cells were treated for 48 hours without or with either 20 (EGb-20) or 200 (EGb-200) ⁇ g/ml EGB 761® or 2 (GKB-2) or 20 (GKB-20) ⁇ g/ml GKB.
- RNA was isolated and loaded onto a 1% formaldehyde gel at a concentration of 10 ⁇ g/lane.
- Northern blots were incubated with 32 P-labeled hPBR probe and exposed to XOMAT Kodak film.
- Top autoradiogram of the blot.
- PBR migrates at 0.9 Kb.
- Bottom relative intensity of the PBR mRNA/28S ribosomal RNA visualized by ethidium bromide staining. The autoradiogram and PBR mRNA quantitation represent one out of two independent experiments.
- FIG. 5 Right, Middle, Left. Recovery of MDA-231 cell proliferation upon removal of EGB 761®.
- MDA-231 cells grown in 96-well plates were washed with PBS and cultured in media supplemented with 10% FBS in the presence or absence of 2 (Left), 20 (Middle) or 200 (Right) ⁇ g/ml EGB 761® for 48 h.
- FIG. 6 Effect of GKB on MDA-231 cell proliferation.
- FIG. 8 Effect of EGB 761® on MDA-231 cell free radical production.
- FIG. 9 Transcriptional response to EGB 761® suggests an effect on genes involved in cell proliferation.
- Results shown represent quantitative analysis of the Atlas human cDNA expression array containing 588 PCR-amplified cDNA fragments (Clontech Inc.). mRNAs were obtained from control or EGB 761® (20 ⁇ g/ml) treated, for 48 h, MDA-231 cells. For normalizing the mRNA abundance, the densitometric values obtained from image analysis were normalized using the housekeeping genes provided in the array. Only consistent significant changes above 30% were considered.
- FIG. 11 A , B, C, D, E, F, G, H PBR expression in MDA-231 xenografts from control and EGB 761® or GKB treated animals.
- Formalin embedded sections of MDA-231 xenografts were immunostained with an anti-PBR antiserum at 1:500 dilution as described in the Materials and Methods section.
- MDA-231 tumors were obtained from animals treated with vehicle (A-D), 50 mg/kg EGB 761® per os (E, G), or 1 mg/kg GKB ip (F, H).
- A shows cells found in the middle of a tumor obtained from vehicle-treated animals where the nuclear localization of the PBR protein can be easily seen (see arrowheads).
- Ginkgo biloba extract as used herein includes a collection of natural molecules, including terpenoids, derived from the leaves of the Ginkgo biloba tree.
- the extract is the specific formulation of Ginkgo biloba extract known as EGB 761®.
- the level of expression of PBR for the purposes of diagnosis or prognosis of a cancer or tumor, can be detected at several levels.
- assays for the detection and quantitation of PBR RNA can be designed, and include northern hybridization assays, in situ hybridization assays, and PCR assays, among others. See e.g., Maniatis, Fitsch and Sambrook, Molecular Cloning; A Laboratory Manual (1982) or DNA Cloning, Volumes I and II (D. N. Glover ed. 1985), or Current Protocols in Molecular Biology, Ausubel, F. M. et al. (Eds), Wiley & Sons, Inc. for the general description of methods for nucleic acid hybridization.
- Polynucleotide probes for the detection of PBR RNA can be designed from the sequence available at accession number L21950 for the human PBR sequence (Riond, J. et al. (1991) Eur. J. Biochem. 195:305-311; Chang, Y. J. et al. (1992) DNA and Cell Biol. 11:471-480).
- the sequence of PBR from other sources such as bovine (Parola, A. L. et al. (1991) J. Biol. Chem 266:14082-14087) and mouse (Garnier, M. et al. (1994) Mol Phar. 45:201-211) are also known.
- the complete sequence of the PBR, normal or mutant, can be used for a probe to detect RNA expression. Alternatively, a portion or portions of the sequence can be used. Methods for designing probes are known in the art. Polynucleotide sequences are preferably homologous to or complementary to a region of the PBR gene, preferably, the sequence of the region from which the polynucleotide is derive is homologous to or complementary to a sequence which is unique to the PBR gene. Whether or not a sequence is unique to the PBR gene can be determined by techniques known to those of skill in the art. For example, the sequence can be compared to sequences in databanks, e.g., GenBank. Regions from which typical DNA sequences may be derived include but are not limited to, for example, regions encoding specific epitopes, as well as non-transcribed and/or non-translated regions.
- PBR ligands or anti-PBR antibodies, or fragments of ligand and antibodies capable of detecting PBR may be labeled using any of a variety of labels and methods of labeling for use in diagnosis and prognosis of disease, such as breast cancer, particularly for assays such as Positron Emission Tomography and magnetic resonance imaging (Leong, D. et al. (1996) Alcohol Clin . Exp. Res. 20: 601-605).
- types of labels which can be used invention include but are not limited to enzyme labels, radioisotopic labels, non-radioactive isotopic labels and chemiluminescent labels.
- radioisotopic labels examples include 3 H, 111 In, 125 I, 32 P, 35 S, 14 C, 57 To, 58 Co, 59 Fe, 75 Se, 152 Eu, 90 Y, 67 Cu, 21 Ci, 211 At, 212 Pb, 47 Sc, 109 Pd, 11 C, 19 F, 123 I, etc.
- non-radioactive isotopic labels examples include 157 Gd, 55 Mn, 162 Dy, 52 Tr, 46 Fe, etc.
- fluorescent labels examples include a 152 Eu label, a fluorescein label, an isothiocyanate label, a rhodamine label, a phycoerythrin label, a phycodyanin label, an allophycocyanin label, a fluorescamine label, etc.
- chemiluminescent labels include a luminal label, an isoluminal label, an aromatic acridinium ester label, an imidazole label, an acridinium salt label, an oxalate ester label, a luciferin label, a luciferase label, etc.
- Ginkgo biloba extracts more specifically EGB 761® and GKB on PBR expression and cell proliferation, particularly in human breast cancer cells.
- MDA-231 which expresses over 60-fold higher levels of PBR ligand binding and mRNA relative to the non-aggressive cell line MCF-7.
- EGB 761® and GKB decreased in a time- and dose-dependent manner PBR expression and cell proliferation in MDA-231 cells whereas EGB 761® and GKB did not affect the MCF-7 cell proliferation to the same degree. This effect was reversible and it was not due to the antioxidant properties of the compounds tested.
- the distinct sub-cellular localization of PBR in the cytoplasm of epithelial cells of normal breast ducts and the absence of staining in the nucleus and the perinuclear area of the aggressive tumor cells provides a simple method for diagnosing the aggressive phenotype of a tumor cell.
- Immunostaining using labeled PBR ligand or labeled PBR antibody or fragment of ligand or antibody capable of binding to PBR and determining the sub-cellular location of PBR in the cellular samples provides yet another diagnostic assay of the present invention.
- antiserum which recognizes PBR can also be used along with a secondary antibody reactive with the primary antibody. Immunostaining assays are well known in the art, and are additionally described in the Examples below with respect to breast cancer cells and biopsies.
- Human breast cancer cell lines (MCF-7 and MDA-231) were obtained from the Lombardi Cancer Center, Georgetown University Medical Center. Cell lines were cultured on polystyrene culture dishes (Corning) and grown in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS).
- DMEM Dulbecco's modified Eagle medium
- FBS fetal bovine serum
- the injectable form (IPS200) of the standardized Ginkgo biloba extract EGB 761® was used. This injectable form is devoid of protocyanidins, which are known to interact with proteins in vitro (Defeuder, 1998 Ullstein Medical).
- the injectable form of EGB 761® and GKB (BN 52021) isolated from EGB 761® were provided by the Institut Henri Beaufour-IPSEN (Paris, France).
- RNA (Northern) Analysis PBR mRNA expression in MDA-231 cells treated with the various compounds was examined by Northern Blot analysis as we previously described (Hardwick, M., et al., 1999, Cancer Research, 59: 831-842). In brief, total cellular RNA was isolated using the RNAzol B reagent (TEL-TEST, Inc., Friendswood, Tex.) and chloroform. 20 ⁇ g of total RNA from each cell line were run on 1% agarose gels and transferred overnight to nylon membranes (S&S Nytran, Schleicher & Schuell, Keene, N.H.) (21).
- hPBR human PBR
- BrdU Cell Proliferation Assays MDA-231 cells were plated on 96-well plates (Corning, Corning, N.J.) at a concentration of approximately 10,000 cells/well (24 h incubation) or approximately 5,000 cells/well (48 h incubation) in DMEM supplemented with 0.1% FBS. The cells were then incubated in 10% FBS with various concentrations of EGB 761® or GKB for the indicated time periods. Differences in cell proliferation were analyzed by measuring the amount of 5-bromo-2′deoxyuridine (BrdU) incorporation determined by the BrdU ELISA (Boehringer Mannheim, Indianapolis, Ind.). Incorporation of BrdU was measured at 450 nm (reference at 690 nm).
- PrdU 5-bromo-2′deoxyuridine
- oxidative stress Analysis of oxidative stress.
- levels of cellular oxidative stress were measured using the fluorescent probe 2,7-dichlorofluorescin diacetate (2,7-DCF; Molecular Probes, Inc., Eugene, Oreg.) as described in Goodman, Y. and Mattson, M. P., Exp. Neurol., 128: 1-12, 1994.
- cells were cultured in 96-well plates and treated for 48 hours with the indicated concentrations of EGB 761®. At the end of the treatment the cells were washed and incubated in the presence of 50 ⁇ M 2,7-DCF in PBS. Fluorescence was then quantified using the Victor 2 quantitative detection fluorometer (EGG-Wallac, Inc., Gaithersburg, Md.).
- the MDA-231 human breast cancer (estrogen insensitive) xenograft model was used for in vivo screening of EGB 761® and GKB. Based on the in vitro data and previously published in vivo data (23) the doses used were 50 mg/kg for the EGB 761® and 1 mg/kg for the GKB.
- Female athymic nude mice NCI/Charles River, Frederick, Md.
- NCI/Charles River, Frederick, Md. are injected subcutaneously with 8 ⁇ 10 6 MDA-231 tumor cells and tumors are allowed to form to a volume of ⁇ 100 to 150 mm 3 . At this time, groups of 10 animals per compound were injected either orally for the EGB 761® or intraperitoneally for the GKB once a day for a month.
- MDA-231 tumors removed from the mice treated with or without EGB 761® or GKB were fixed in 10% buffered formalin. Tumors were sectioned and then placed on glass slides and processed as we previously described (19). For immunohistochemistry with anti-PBR primary antibodies, tissue sections were treated with a 30% H 2 O 2 /methanol mixture (1:9 ratio) for 5 min at room temperature to neutralize endogenous peroxidase activity and then washed well with PBS. Primary antibody in 10% calf serum in PBS was added to sections at a concentration of 1:500 at RT for 1 h.
- EGB 761® and GKB reduce the PBR mRNA Expression in MDA-231 Human Breast Cancer Cells.
- RNA (Northern) blot analysis was performed in order to determine if the differences seen in PBR ligand binding between the control and the EGB 761®- or GKB-treated cells reflect an effect on PBR mRNA expression. As shown in FIG. 3 , both EGB 761® and GKB reduced PBR mRNA levels. This result fits with the results presented above on the PBR ligand binding expression.
- EGB 761® and GKB Inhibit MDA-231 Cell Proliferation Using the Bromodeoxyuridine (BrdU) Cell Proliferation ELISA (Boehringer-Mannheim, Indianapolis, Ind.), we examined the effect of increasing concentrations of EGB 761® on MDA-231 cell proliferation.
- FIG. 4 shows that EGb-761 inhibits in a concentration- and time-dependent manner the MDA-231 cell proliferation. This effect of EGB 761® was reversible, even for the highest concentration of EGB 761® used. ( FIG. 5 ).
- EGB 761® and GKB Do Not Have The Same Level of Inhibition against MCF-7 Cell Proliferation as They Do against MDA-231 Cell Proliferation.
- the non-aggressive MCF-7 cells contain extremely low ( ⁇ 60 fold) PBR levels, as determined by both ligand binding studies and mRNA analyses, we examined whether EGB 761® and GKB affect the MCF-7 cell proliferation rate to the same degree as it affects MDA-231 cell proliferation rate.
- FIG. 7 clearly shows that neither EGB 761® nor GKB affect MCF-7 cell proliferation to the same degree as they affect the MDA-231 cell proliferation.
- EGB 761® Regulates the MDA-231 Transcriptional Program Related to Cell Proliferation.
- the results presented above indicate that EGB 761® and GKB inhibit PBR expression and cell proliferation in the PBR-rich and highly aggressive MDA-231 breast cancer cells.
- the non-aggressive MCF-7 cells which contain extremely low PBR levels, did not respond to EGB 761® treatment to the same degree as that of the MDA-231 breast cancer cells.
- EGB 761® (20 ⁇ g/ml for 48 hours) on MDA-231 cells was specific for PBR or whether other genes involved in cell proliferation were affected by the treatment, we used a cDNA array representing 588 distinct human genes.
- FIG. 11 (A-D) shows horseradish peroxidase (HRP) staining of the PBR antiserum used to detect the 18,000 molecular weight protein in MDA-231 xenografts from vehicle-treated animals. The hematoxylin counterstain was omitted in order to distinguish the nuclear localization of PBR (19) in the tumors.
- FIG. 11A shows the middle of a tumor where the nuclear localization of the 18,000 PBR protein can be easily seen (see arrowheads).
- FIG. 11B shows the immunostaining seen in the edge of the tumor obtained from vehicle-treated animals.
- a higher magnification of the immunostaining seen in the edge of the tumor obtained from vehicle-treated animals is shown in FIG. 1C
- a control treated with a non-specific antiserum is shown in FIG. 11D .
- Treatment with either EGB 761® ( FIG. 11E ) or GKB ( FIG. 11F ) reduced the nuclear PBR expression present in cells found in the middle of the tumor.
- EGB 761® FIG. 11G
- GKB FIG. 11H
- p120 is used as a prognostic indicator in breast cancer patients and prostate adenocarcinomas (Perlaky, L., et al., Cancer Res., 52: 428-436, 1992; Zhuang, S. H. et al., Endocrinology, 139: 1197-1207, 1998). More importantly, however, p120 is an immunocytochemical marker of proliferating cells. Down-regulation of this proliferation marker by 68% thus confirms our data demonstrating that EGB 761® inhibits MDA-231 cell proliferation.
- c-Myc and n-Myc Two members of the Myc family of transcription factors, c-Myc and n-Myc, were found to be grossly altered in this experiment. Expression of the proto-oncogene c-Myc was increased by 75% while expression of n-Myc was reduced by 74%. Both of these genes are overexpressed in several cancer types (Kim, C. J., et al., Virchows Arch., 434: 301-305, 1999; Dang, C. V., Mol. Cel. Biol., 19: 1-11, 1999) and are strongly correlated with tumor cell proliferation. Previous studies have shown that arrest of neuroblastoma cell growth by the tyrosine kinase inhibitor genistein is accompanied by down-regulation of n-Myc expression.
- prothymosin ⁇ prothymosin ⁇
- proT ⁇ prothymosin ⁇
- expression of proT ⁇ is reduced by 79% rather than increased, as might be predicted by up-regulation of c-Myc.
- expression of other c-Myc target genes such as cdc25A, cyclin A, and cyclin E are unaffected by treatment of MDA-231 cells with EGB 761®, suggesting either a treatment-specific or a cell line-specific short circuit in c-Myc-regulated gene transcription.
- EGB 761® EGB 761®
- c-Myc transcriptional regulation is under the control of APC and ⁇ -catenin. However, both of these genes are down-regulated by EGB 761® in MDA-231 cells (59 and 58%, respectively) while c-Myc is up-regulated. While some of this data appears to be contradictory, much of the published data on the role of c-Myc in cell proliferation, differentiation, and cell death also appears contradictory.
- EGB 761® Other important signaling molecules are also down-regulated by EGB 761®.
- Expression of the adapter molecule Grb2 is reduced by 70%.
- Grb2 plays an important role in cellular signaling by physically linking signal transducers such as receptor tyrosine kinases to the Ras/MAPK pathway.
- signal transducers such as receptor tyrosine kinases
- MAPK pathway expression of the MAP/ERK family member ERK2 is down-regulated by 46% and expression of the c-Jun transcription factor is reduced by 78%.
- EGB 761® is a suppressor of AP-1 transcription factor stimulated by phorbol esters.
- integrins are a large family of cell-cell and cell-extracellular matrix adhesion receptors that are composed of two transmembrane glycoprotein subunits, one ⁇ - and one ⁇ -subunit. All of the integrins represented in Table I are involved in the regulation of cell proliferation in some way. For example, integrin ⁇ M is part of the elastase receptor.
- ONO-5046 an elastase inhibitor, suppresses the proliferation of polyoma virus- and Kirsten sarcoma virus-transformed BALB/c3T3 cells and of Capan-1 pancreatic carcinoma cells.
- integrin ⁇ 4 has been implicated in the accumulation of distal metastases in melanoma, sarcoma, and lymphoma cell models. It is important to emphasize that integrins function as heterodimers of one ⁇ - and one ⁇ -subunit. Reduced expression of either the ⁇ - or the ⁇ -subunit is clearly important in the regulation of integrin receptor function.
- EGB 761® The expression of some key growth factor genes, such as the hepatocyte growth factor-like and EGF-like growth factor, were also reduced by EGB 761®. It is possible that the EGB 761®-induced inhibition of cell proliferation may be due to the reduced expression of these growth factors that may act as autocrine regulators of cell growth.
- EGB 761® and GKB are intended to be provided to recipient patient in an amount sufficient to combat cancer in said patient or in an amount sufficient to affect the expression (negatively or positively) of the gene products listed in Table 1, hereinabove.
- An amount is said to be sufficient to combat cancer if the dosage, route of administration, etc. of the EGB 761® and GKB are sufficient to influence such a response.
- a composition is said to be “pharmacologically acceptable” if its administration can be tolerated by a recipient patient.
- Such an agent is said to be administered in a “therapeutically effective amount” if the amount administered is physiologically significant.
- An agent is physiologically significant if its presence results in a detectable change in the physiology of a recipient patient.
- EGB 761® and GKB can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby these materials, or their functional derivatives are optionally combined in admixture with a pharmaceutically acceptable carrier vehicle.
- Suitable vehicles and their formulation, inclusive of other human proteins, e.g., human serum albumin, are described, for example, in Remington's Pharmaceutical Sciences (16 TH ED., Osol, A. ed., Mack Easton Pa. (1980)).
- a pharmaceutically acceptable composition suitable for effective administration such compositions will contain an effective amount of the above-described compounds together with a suitable amount of carrier vehicle.
- Control release preparations may be achieved through the use of polymers to complex or absorb the compounds.
- the controlled delivery may be exercised by selecting appropriate macromolecules (for example polyesters, polyamino acids, polyvinyl, pyrrolidone, ethylenevinylacetate, methylcellulose, carboxymethylcellulose, or protamine sulfate) and the concentration of macromolecules as well as the method of incorporation in order to control release.
- Another possible method to control the duration of action by controlled release preparations is to incorporate the compounds of the present invention into particles of a polymeric material such as polyesters, polyamino acids, hydrogels, poly(lactic acid) or ethylene vinylacetate copolymers.
- microcapsules prepared, for example, interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly (methylmethacrylate) microcapsules, respectively, or in colloidal drug delivery systems, for example, liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules or in macroemulsions.
- interfacial polymerization for example, hydroxymethylcellulose or gelatin-microcapsules and poly (methylmethacrylate) microcapsules, respectively
- colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules or in macroemulsions.
- EGB 761® and isolated GKB can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual or topical routes of administration and can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.
- parenteral e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant
- nasal, vaginal, rectal, sublingual or topical routes of administration can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
- the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch.
- Such dosage forms can also comprise, as is normal practice, additional substances other than such inert diluents, e.g., lubricating agents such as magnesium stearate.
- the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, the elixirs containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.
- Preparations according to this invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions.
- non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate.
- Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
- compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as coca butter or a suppository wax.
- compositions for nasal or sublingual administration are also prepared with standard excipients well known in the art.
- the dosage of EGB 761® or isolated GKB in the compositions of this invention may be varied; however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained.
- the selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment.
- the dose can be administered as a single dose or divided into multiple doses.
- An effective dose amount of either EGB 761® or isolated GKB depends upon the condition being treated, the route of administration chosen and ultimately will be decided by the attending physician or veterinarian.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- The present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated ginkgolide B (GKB), a component of the extract of Ginkgo biloba leaves in a method for decreasing the expression of peripheral-type benzodiazepine_receptor (PBR) in cells of a patient in need thereof. Further, the present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated GKB in a method for decreasing the proliferation of cancer cells in a patient in need thereof. More particularly, the present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated GKB in a method of decreasing cancer cell proliferation in a patient in need thereof wherein said cancer cell is human breast cancer cells. Even more particularly, the present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated GKB in a method of decreasing cancer cell proliferation in a patient in need thereof wherein said cancer cell are of the aggressive and invasive phenotype and expresses high levels of PBR in comparison to non-aggressive cancer cells.
- In another aspect, the present invention is directed to the use of extract of Ginkgo biloba leaves to decrease the expression of thirty-five (35) gene products as is further detailed, hereinbelow.
- It is preferred that a particular formulation of Ginkgo biloba leaves extract known as EGB 761® (a product of IPSEN, Paris, France) be a constituent in a composition or used in a method of the present invention.
- Ginkgo biloba is one of the most ancient trees and extracts from its leaves have been used in traditional medicine for several hundred years. There are numerous studies describing the beneficial effects of Ginkgo biloba extracts on patients with disturbances in vigilance, memory, and cognitive functions associated with aging and senility, and on those with all types of dementias, mood changes, and the ability to cope with daily stressors. A standardized extract of Ginkgo biloba leaves, termed EGB 761®, has been used in most of these studies. This extract is also known to have cardioprotective effects (DeFeudis F. V. Ginkgo biloba extract (EGB 761®): from chemistry to clinic. Ullstein Medical, Wisbaden, Germany. 400 pp. 1998; Tosaki, A., Droy-Lefaix, M. T., Pali, T., and Das, D. K., Free Rad. Biol. Med., 14: 361-370, 1993). These effects have been attributed, at least in part, to the free radical scavenging properties of EGb761®, probably due to the presence of flavonoid or terpenoid constituents in the extract. Recent in vivo and in vitro studies demonstrated that the terpene constituents of EGB 761®, ginkgolides and bilobalide, have anti-oxidant properties (Pietri, S., Maurelli, E., Drieu, K., and Culcasi, M., J. Mol. Cell. Cardiol., 29: 733-742, 1997; Yao, Z., Boujrad, N., Drieu, K., and Papadopoulos, V., Adv. Ginkgo Biloba Res. 7: 129-138, 1998). Other studies of EGB 761® have reported medicinal value of the product in the treatment of a variety of clinical disorders including cerebrovascular and peripheral vascular insufficiencies associated with aging and senility. See e.g., Ginkgo biloba Extract (EGB 761®) Pharmacological Activities and Clinical Applications, DeFeudis, F. V., Eds, Elsevier, 1991; and Ullstein Medical 1998, Ginkgo biloba extract (EGB 761®), Eds. Wiesbaden, DeFeudis, F. V. The extract contains 24% ginkgo-flavone glycosides, 6% terpene lactones (ginkgolides and bilobalide), about 7% proanthocyanidins and several other constituents. See Boralle, N., et al., In: Ginkgolides, Chemistry, Biology, Pharmacology and Clinical perspectives, Ed: Braquet, P., J. R. Prous Science Publishers, 1988.
- Tumor progression is a multi-step process in which normal cells gradually acquire more malignant phenotypes, including the ability to invade tissues and form metastases, the primary cause of mortality in breast cancer. During this process, the “aberrant” expression of a number of gene products may be the cause or the result of tumorigenesis. Considering that the first step of tumor progression is cell proliferation, it can be proposed that tumorigenesis and malignancy are related to the proliferative potential of tumoral cells.
- Studies in a number of tumors such as rat brain containing glioma tumors (Richfield, E. K. et al. (1988) Neurology 38:1255-1262), colonic adenocarcinoma and ovarian carcinoma (Katz, Y. et al. (1988) Eur. J. Pharmacol. 148:483-484 and Katz, Y. et al. (1990) Clinical Sci. 78:155-158) have shown an abundance of peripheral-type benzodiazepine receptors (PBR) compared to normal tissue. Moreover, a 12-fold increase in PBR density relative to normal parenchyma, was found in human brain glioma or astrocytoma (Cornu, P. et al. (1992) Acta Neurochir. 199:146-152). The authors suggested that PBR densities may reflect the proliferative activity of the receptor in these tissues. Recently, the involvement of PBR in cell proliferation was further shown (Neary, J. T. et al. (1995) Brain Research 675:27-30; Miettinen, H. et al. (1995) Cancer Research 55:2691-2695), and its expression of human astrocytic tumors was found to be associated with tumor malignancy and proliferative index (Miettinen, H. et al. supra; Alho, H. (1994) Cell Growth Different. 5:1005-1014). Further studies have shown that PBR receptors are abundant in human glioblastomas (Broaddus, W. C., et al., Brain Research, Vol. 518:199-208, 1990; and Pappata, S., et al., J. Nuclear Med., 32:1608-1610, 1991).
- PBR is an 18-kDa protein discovered as a class of binding sites for benzodiazepines distinct from the GABA neurotransmitter receptor (Papadopoulos, V. (1993) Endocr. Rev. 14:222-240). PBR are extremely abundant in steroidogenic cells and found primarily on outer mitochondrial membranes (Anholt, R. et al. (1986) J. Biol. Chem. 261:576-583). PBR is thought to be part of the multimeric complex composed of the 18-kDa isoquinoline-binding protein and the 34-kDa pore-forming voltage-dependent anion channel protein, preferentially located on the outer/inner mitochondrial membrane contact sites (McEnery, M. W. et al. Proc. Natl. Acad. Sci. U.S.A. 89:3170-3174; Garnier, M. et al. (1994) Mol. Pharmacol. 45:201-211; Papadopoulos, V. et al. (1994) Mol. Cel. Endocr. 104:R5-R9). Drug ligands of PBR, upon binding to the receptor, stimulate steroid synthesis in steroidogenic cells in vitro (Papadopoulos, V. et al. (1990) J. Biol. Chem. 265:3772-3779; Ritta, M. N. et al. (1989) Neuroendocrinology 49:262-266; Barnea, E. R. et al. (1989) Mol. Cell Endocr. 64:155-159; Amsterdam, A. and Suh, B. S. (1991) Endocrinology 128:503-510; Yanagibashi, K. et al. (1989) J. Biochem. (Tokyo) 106:1026-1029). Likewise, in vivo studies showed that high affinity PBR ligands increase steroid plasma levels in hypophysectomized rats (Papadopoulos V. et al (1997) Steroids 62:21-28). Further in vitro studies on isolated mitochondria provided evidence that PBR ligands, drug ligands, or the endogenous PBR ligand, the polypeptide diazepam binding inhibitor (BDI) (Papadopoulos, V. et al. (1997) Steroids 62:21-28), stimulate pregnenolone formation by increasing the rate of cholesterol transfer from the outer to the inner mitochondrial membrane (Krueger, K. E. and Papadopoulos, V. (1990) J. Biol. Chem 265:15015-15022; Yanagibashi, K. et al. (1988) Endocrinology 123: 2075-2082; Besman, M. J. et al. (1989) Proc. Natl. Acad. Sci. U.S.A. 86:4897-4901; Papadopoulos, V. et al. (1991) Endocrinology 129:1481-1488).
- Based on the amino acid sequence of the 18-kDa PBR, a three dimensional model was developed (Papadopoulos, V. (1996) In: The Leydig Cell. Payne, A. H. et al. (eds) Cache River Press, IL, pp. 596-628). This model was shown to accomodate a cholesterol molecule and function as a channel, supporting the role of PBR in cholesterol transport. Recently we demonstrated the role of PBR in steroidogenesis by generating PBR negative cells by homologous recombination (Papadopoulos, V. et al. (1997) J. Biol. Chem. 272:32129-32135) that failed to produce steroids. However, addition of the hydrosoluble analogue of cholesterol, 22R-hydroxycholesterol, recovered steroid production by these cells, indicating that the cholesterol transport mechanism was impaired. Further cholesterol transport experiments in bacteria expressing the 18-kDa PBR protein provided definitive evidence for a function as a cholesterol channel/transporter (Li and Papadopoulos, V. et al. (1998) Endocrinology).
- We hypothesized that the peripheral-type benzodiazepine receptor is part of the changes in cellular and molecular functions that account for the increased aggressive behavior in cancer, and we chose to examine this hypothesis in human breast cancer. Breast cancer is the most common neoplasm and the leading cause of cancer-related deaths for women in most developing countries (Lippman, M. E. (1993) Science 259:631-632), affecting nearly 184,000 women, with over 46,000 deaths annually in the U.S. alone (American Cancer Society, 1996). Human breast cells are unlike brain and gonadal cells and cannot produce steroids, but like many other cells in the body, are able to metabolize steroids.
- Increased PBR expression correlates with increased aggressive behavior of tumor cells. Invasive tumors invade and grow locally but they do not metastasize. However, the aggressive tumors have the ability to invade and metastasize through the blood vessels to different places of the human body. Tumor metastasis into vital organs (such as lungs) is the most common cause of death.
- The correlation between high levels of expression of PBR and metastatic potential in for human breast cancer is shown in copending U.S. application Ser. No. 09/047,652 filed Mar. 25, 1998, in which Vassilios Papadopoulos of the instant application is a co-inventor. However, due to the involvement of PBR in cell proliferation, and the expression of PBR in all cells, it is likely that this correlation would exist for other solid tumors and cancers such as prostate cancer, colon cancer, brain tumors, and tumors in steroid producing tissues such as gonadal tumors, to name a few.
- In one aspect, the present invention is directed to a method of combating cancer in a patient in need of such combating, wherein the cancer is caused by the deregulation of expression of proteins having a role in regulating tumor cells, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.
- In another aspect, the present invention is directed to a method of combating the proliferation of cancer cells in a patient in need of such combating, wherein the proliferation is caused by the deregulation of expression of proteins having a role in regulating tumor cells, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.
- In another aspect, the present invention is directed to a method of combating the proliferation of cancer cells in a patient in need of such combating, wherein the proliferation is caused by over-expression of proteins having a role in regulating tumor cells, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.
- In another aspect, the present invention is directed to a method of combating the proliferation of cancer cells having an aggressive phenotype in a patient in need of such combating, wherein the proliferation is caused by the over-expression of peripheral-type benzodiazepine receptor protein, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.
- In another aspect, the present invention is directed to a method of combating the proliferation of cancer cells, where the proliferation is caused by the over-expression of oncogenes, by decreasing the expression of said oncogenes in a patient in need of such combating, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient. A preferred method of the immediately foregoing method is where said oncogenes are one or more of APC, PE-1, RhoA and c-Jun.
- In another aspect, the present invention is directed to a method of decreasing the expression of peripheral-type benzodiazepine receptor in cancer cells in a patient in need of such decreasing, wherein said cancer cells express an abnormal level of peripheral-type benzodiazepine receptor relative to normal cancer cells, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient. A preferred method of the immediately foregoing method is where the cancer cells are human breast cancer cells; human glioblastomas; human brain tumors; human astrocytomas; human colonic carcinoma; human colonic adenocarcinoma; human ovarian carcinomas; and human hepatocellular carcinoma.
- In another aspect, the present invention is directed to a method of decreasing the expression of peripheral-type benzodiazepine receptor mRNA in cancer cells in a patient in need of such decreasing, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.
- In another aspect, the present invention is directed to a method of increasing the expression of c-Myc protooncogene in a patient in need of such increasing, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.
- In another aspect, the present invention is directed to a method of decreasing the expression of cell cycle regulators prothymosin-α, CDK2, p55CDC, myeloblastin and p120 proliferating-cell nuclear antigen (PCNA) in a patient in need of such decreasing, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.
- In another aspect, the present invention is directed to a method of decreasing the expression of intracellular signal transduction modulators NET1 and ERK2, in a patient in need of such decreasing, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.
- In another aspect, the present invention is directed to a method of decreasing the expression of apoptosis-related proteins Adenosine A2A Receptor, Flt3 ligand, Grb2, Clusterin, RXR-β, Glutathione S-transferase P, N-Myc, TRADD, SGP-2 and NIP-1, in a patient in need of such decreasing, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.
- In another aspect, the present invention is directed to a method of decreasing the expression of transcription factors Id-2, ATF-4, ETR101 and ETR-103 in a patient in need of such decreasing, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.
- In another aspect, the present invention is directed to a method of decreasing the expression of growth factors macrophage colony-stimulating factor-1, heparin-binding EGF-like growth factor, hepatocyte growth factor-like protein and inhibin α, in a patient in need of such decreasing, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.
- In another aspect, the present invention is directed to a method of decreasing the expression of cell adhesion molecules CD19 B-lymphocyte antigen, L1CAM, β-catenin, integrin subunits α3, α4, α6, β5, and αM, in a patient in need of such decreasing, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.
- In another aspect, the present invention is directed to a method of decreasing the expression of genes APC, PE-1, RhoA, c-Jun, prothymosin-α, CDK2, p55CDC, myeloblastin, p120 proliferating-cell nuclear antigen (PCNA), NET1, ERK2, Adenosine A2A Receptor, Flt3 ligand, Grb2, Clusterin, RXR-β, Glutathione S-transferase P, N-Myc, TRADD, SGP-2, NIP-1, Id-2, ATF-4, ETR-101, ETR-103, macrophage colony-stimulating factor-1, heparin-binding EGF-like growth factor, hepatocyte growth factor-like protein, inhibin α, CD19 B-lymphocyte antigen, L1CAM, β-catenin, and integrin subunits α3, α4, α6, β5, and αM, in a patient in need of such decreasing, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.
- In another aspect, the present invention is directed to a pharmaceutical composition comprising an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B for combating cancer and a pharmaceutically acceptable carrier or diluent.
- Of all of the foregoing methods and compositions of the present invention, a preferred embodiment of each is where the Ginkgo biloba extracts is EGB 761®.
- Further, of all the foregoing methods and compositions of the present invention, it is preferred that Ginkgolide B is used.
- The file of this patent contains at least one drawing executed in color (
FIG. 11 ). Copies of this patent with color drawing(s) will be provided by the Patent and Trademark Office upon request and payment of the necessary fee. -
FIG. 1 . Effect of various concentrations of EGB 761® on MDA-231 PBR ligand binding capacity. MDA-231 cells were cultured as described under Materials and Methods. Cells were treated with the indicated concentrations of the injectable form of EGB 761®. At the indicated time periods cells were collected and PBR ligand binding characteristics were determined by Scatchard analysis. Data points represent the mean±S.D. of three independent experiments carried out in triplicate. -
FIG. 2 . Effect of various concentrations of GKB on MDA-231 PBR ligand binding capacity. MDA-231 cells were cultured as described under Materials and Methods. Cells were treated with the indicated concentrations of GKB for 48 hours. At the indicated time periods cells were then collected and PBR ligand binding characteristics were determined by Scatchard analysis. Data points represent the mean±S.D. of two independent experiments carried out in triplicate. -
FIG. 3 . Effect of EGB 761® and GKB on PBR mRNA levels in MDA-231 cells. Cells were treated for 48 hours without or with either 20 (EGb-20) or 200 (EGb-200) μg/ml EGB 761® or 2 (GKB-2) or 20 (GKB-20) μg/ml GKB. At the end of the incubation total RNA was isolated and loaded onto a 1% formaldehyde gel at a concentration of 10 μg/lane. Northern blots were incubated with 32P-labeled hPBR probe and exposed to XOMAT Kodak film. Top, autoradiogram of the blot. PBR migrates at 0.9 Kb. Bottom, relative intensity of the PBR mRNA/28S ribosomal RNA visualized by ethidium bromide staining. The autoradiogram and PBR mRNA quantitation represent one out of two independent experiments. -
FIG. 4 . Effect of EGB 761® on MDA-231 cell proliferation. MDA-231 cells grown in 96-well plates were washed with PBS and cultured in media supplemented with 10% FBS in the presence or absence of the indicated concentrations of EGB 761®. 4 h prior to the end of incubation, bromodeoxyuridine (BrdU) was added to each well. Incorporation of BrdU was measured at 450 nm (reference=700 nm). Data points represent the mean±S.D. of four independent experiments carried out in quadruplicate. One-way ANOVA indicates that MDA-231 cell proliferation was significantly altered by treatment with EGB 761® at 48, 72 and 96 h timepoints (P<0.0001). -
FIG. 5 Right, Middle, Left. Recovery of MDA-231 cell proliferation upon removal of EGB 761®. MDA-231 cells grown in 96-well plates were washed with PBS and cultured in media supplemented with 10% FBS in the presence or absence of 2 (Left), 20 (Middle) or 200 (Right) μg/ml EGB 761® for 48 h. At the end of the treatment the cells were washed and incubated in EGB 761®-free media for 48 h. 4 h prior to the end of incubation, bromodeoxyuridine (BrdU) was added to each well. Incorporation of BrdU was measured at 450 nm (reference=700 nm). Data points represent the mean±S.D. of two independent experiments carried out in quadruplicate. -
FIG. 6 . Effect of GKB on MDA-231 cell proliferation. MDA-231 cells grown in 96-well plates were washed with PBS and cultured in media supplemented with 10% FBS in the presence or absence of either 2 μg/ml or 20 μg/ml GKB for 48 hours. 4 h prior to the end of incubation, bromodeoxyuridine (BrdU) was added to each well. Incorporation of BrdU was measured at 450 nm (reference=700 nm). Data points represent the mean±S.D. of two independent experiments carried out in quadruplicate. One-way ANOVA indicates that MDA-231 cell proliferation was significantly altered by treatment with GKB (P<0.0001). -
FIG. 7 . Effect of EGB 761® and GKB on MCF-7 cell proliferation. MCF-7 cells were grown in 96-well plates as described inFIG. 4 for the MDA-231 cells. MCF-7 cells were treated for 48 hours without or with either 20 (EGb-20) or 200 (EGb-200) μg/ml EGB 761®, or 2 (GKB-2) or 20 (GKB-20) μg/ml GKB. 4 h prior to the end of incubation, bromodeoxyuridine (BrdU) was added to each well. Incorporation of BrdU was measured at 450 nm (reference=700 nm). Data points represent the mean±S.D. of two independent experiments carried out in quadruplicate. One-way ANOVA indicates that MCF-7 cell proliferation was altered to a lesser degree than the MDA-231 cell proliferation by treatment with EGB 761® or GKB. -
FIG. 8 . Effect of EGB 761® on MDA-231 cell free radical production. MDA-231 cells were treated for 48 hours with 2 (EGb-2), 20 (EGb-20) or 200 (EGb-200) μg/ml of EGB 761®. The cells were then washed and the levels of cellular oxidative stress were measured using the fluorescent probe DCF as described under Materials and Methods. Results shown are means±S.D. (n=4). Statistical analysis indicated that the effect of EGB 761® was not significant. -
FIG. 9 . Transcriptional response to EGB 761® suggests an effect on genes involved in cell proliferation. Results shown represent quantitative analysis of the Atlas human cDNA expression array containing 588 PCR-amplified cDNA fragments (Clontech Inc.). mRNAs were obtained from control or EGB 761® (20 μg/ml) treated, for 48 h, MDA-231 cells. For normalizing the mRNA abundance, the densitometric values obtained from image analysis were normalized using the housekeeping genes provided in the array. Only consistent significant changes above 30% were considered. -
FIG. 10 . Growth of MDA-231 xenografts in nude mice following either EGB 761® or GKB treatments. Animals were treated either orally with 50 mg/kg EGB 761® or ip with 1 mg/kg GKB once a day for a month starting with 100-150 mm3 volume MDA-231 tumors. After the end of the treatment the animals were kept for 30 more days and then the animals were sacrificed onday 60. Data shown are means±S.E.M. (n=10). Statistical analysis indicated that the effects of EGB 761® and GKB were significant compared to their respective controls (p<0.05). -
FIG. 11 A , B, C, D, E, F, G, H. PBR expression in MDA-231 xenografts from control and EGB 761® or GKB treated animals. Formalin embedded sections of MDA-231 xenografts were immunostained with an anti-PBR antiserum at 1:500 dilution as described in the Materials and Methods section. MDA-231 tumors were obtained from animals treated with vehicle (A-D), 50 mg/kg EGB 761® per os (E, G), or 1 mg/kg GKB ip (F, H). A shows cells found in the middle of a tumor obtained from vehicle-treated animals where the nuclear localization of the PBR protein can be easily seen (see arrowheads). B shows the immunostaining seen in cells present in the edge of the tumor obtained from vehicle-treated animals. A higher magnification of the immunostaining seen in the cells present in the edge of the tumor obtained from vehicle-treated animals is shown in C. D represents a control treated with a non-specific antiserum. E shows the PBR immunostaining in cells found in the middle of the tumor obtained from animals treated with EGB 761®. F shows the PBR immunostaining in cells found in the middle of the tumor obtained from animals treated with GKB. G shows the PBR immunostaining in cells found in the edge of the tumor obtained from animals treated with EGB 761®. H shows the PBR immunostaining in cells found in the middle of the tumor obtained from animals treated with GKB. Arrowheads indicate nuclei. Magnification is ×75 for A, B, C, E, F, G, and H and ×150 for C. - The term “ginkgo terpenoid” includes all of the naturally occurring terpenes which are derived from the gymnosperms tree Ginkgo biloba as well as synthetically produced ginkgo terpenoids and pharmaceutically active derivatives and salts thereof and mixtures thereof. Examples of ginkgo terpenoids include ginkgolides. Examples of ginkgo terpenoids are disclosed in Ginkgolides, Chemistry, Biology, Pharmacology, and Clinical Perspectives, J. R. Provs. Science Publishers, Edited by P. Braguet (1988); F. V. DeFeudis, Ginkgo Biloba Extract (EGB 761®); Pharmacological Activities and Clinical Applications, Elsevier, Chapter II (1991).
- The term “ginkgolide” as used herein include the various ginkgolides disclosed in the books cited above as well as non-toxic pharmaceutically active derivatives thereof. Examples of ginkgolide derivatives include tetrahydro derivatives, acetyl derivatives, and alkyl esters such as the monoacetate derivatives and triacetate derivatives disclosed in Okabe, et al., J. Chem. Soc. (c), pp. 2201-2206 (1967). Ginkgolide B has the following structure and as used herein, refers to isolated ginkgolide B:
- The term “Ginkgo biloba extract” as used herein includes a collection of natural molecules, including terpenoids, derived from the leaves of the Ginkgo biloba tree. Preferably, the extract is the specific formulation of Ginkgo biloba extract known as EGB 761®.
- The term “combating” as used herein means preventing, inhibiting and or decreasing whatever the word “combating” acts upon, e.g., combating cancer cell proliferation means that the cancers cells are prevented and inhibited from proliferating further and or the degree or rate of proliferation is decreased.
- The level of expression of PBR, for the purposes of diagnosis or prognosis of a cancer or tumor, can be detected at several levels. Using standard methodology well known in the art, assays for the detection and quantitation of PBR RNA can be designed, and include northern hybridization assays, in situ hybridization assays, and PCR assays, among others. See e.g., Maniatis, Fitsch and Sambrook, Molecular Cloning; A Laboratory Manual (1982) or DNA Cloning, Volumes I and II (D. N. Glover ed. 1985), or Current Protocols in Molecular Biology, Ausubel, F. M. et al. (Eds), Wiley & Sons, Inc. for the general description of methods for nucleic acid hybridization. Polynucleotide probes for the detection of PBR RNA can be designed from the sequence available at accession number L21950 for the human PBR sequence (Riond, J. et al. (1991) Eur. J. Biochem. 195:305-311; Chang, Y. J. et al. (1992) DNA and Cell Biol. 11:471-480). The sequence of PBR from other sources such as bovine (Parola, A. L. et al. (1991) J. Biol. Chem 266:14082-14087) and mouse (Garnier, M. et al. (1994) Mol Phar. 45:201-211) are also known.
- The complete sequence of the PBR, normal or mutant, can be used for a probe to detect RNA expression. Alternatively, a portion or portions of the sequence can be used. Methods for designing probes are known in the art. Polynucleotide sequences are preferably homologous to or complementary to a region of the PBR gene, preferably, the sequence of the region from which the polynucleotide is derive is homologous to or complementary to a sequence which is unique to the PBR gene. Whether or not a sequence is unique to the PBR gene can be determined by techniques known to those of skill in the art. For example, the sequence can be compared to sequences in databanks, e.g., GenBank. Regions from which typical DNA sequences may be derived include but are not limited to, for example, regions encoding specific epitopes, as well as non-transcribed and/or non-translated regions.
- PBR ligands or anti-PBR antibodies, or fragments of ligand and antibodies capable of detecting PBR may be labeled using any of a variety of labels and methods of labeling for use in diagnosis and prognosis of disease, such as breast cancer, particularly for assays such as Positron Emission Tomography and magnetic resonance imaging (Leong, D. et al. (1996) Alcohol Clin. Exp. Res. 20: 601-605). Examples of types of labels which can be used invention include but are not limited to enzyme labels, radioisotopic labels, non-radioactive isotopic labels and chemiluminescent labels.
- Examples of suitable enzyme labels include malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast-alcohol dehydrogenase, alpha-glycerol phosphate dehydrogenase, triose phosphate insomerase, peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase, acetylcholine esterase, etc.
- Examples of suitable radioisotopic labels include 3H, 111In, 125I, 32P, 35S, 14C, 57To, 58Co, 59Fe, 75Se, 152Eu, 90Y, 67Cu, 21Ci, 211At, 212Pb, 47Sc, 109Pd, 11C, 19F, 123I, etc.
- Examples of suitable non-radioactive isotopic labels include 157Gd, 55Mn, 162Dy, 52Tr, 46Fe, etc.
- Examples of suitable fluorescent labels include a 152Eu label, a fluorescein label, an isothiocyanate label, a rhodamine label, a phycoerythrin label, a phycodyanin label, an allophycocyanin label, a fluorescamine label, etc.
- Examples of chemiluminescent labels include a luminal label, an isoluminal label, an aromatic acridinium ester label, an imidazole label, an acridinium salt label, an oxalate ester label, a luciferin label, a luciferase label, etc.
- We examined herein the effect of Ginkgo biloba extracts, more specifically EGB 761® and GKB on PBR expression and cell proliferation, particularly in human breast cancer cells. We used the highly aggressive cell line MDA-231, which expresses over 60-fold higher levels of PBR ligand binding and mRNA relative to the non-aggressive cell line MCF-7. EGB 761® and GKB decreased in a time- and dose-dependent manner PBR expression and cell proliferation in MDA-231 cells whereas EGB 761® and GKB did not affect the MCF-7 cell proliferation to the same degree. This effect was reversible and it was not due to the antioxidant properties of the compounds tested.
- The determination of elevated levels of PBR is done relative to a sample with no detectable tumor. This may be from the same patient or a different patient. For example, a first sample may be collected immediately following surgical removal of a solid tumor. Subsequent samples may be taken to monitor recurrence of tumor growth and/or tumor cell proliferation. Additionally, other standards may include cells of varying aggressive phenotype such that an increase or decrease in aggressive phenotype can be accessed.
- The distinct sub-cellular localization of PBR in the cytoplasm of epithelial cells of normal breast ducts and the absence of staining in the nucleus and the perinuclear area of the aggressive tumor cells provides a simple method for diagnosing the aggressive phenotype of a tumor cell. Immunostaining using labeled PBR ligand or labeled PBR antibody or fragment of ligand or antibody capable of binding to PBR and determining the sub-cellular location of PBR in the cellular samples provides yet another diagnostic assay of the present invention. In addition, antiserum which recognizes PBR can also be used along with a secondary antibody reactive with the primary antibody. Immunostaining assays are well known in the art, and are additionally described in the Examples below with respect to breast cancer cells and biopsies.
- An increase in the level of PBR is determined when the level of PBR in a tumor cell is about 2-3 times the level of PBR in the normal cell, up to about 10-100 times the amount of PBR in a normal cell.
- Cell Culture and Treatments. Human breast cancer cell lines (MCF-7 and MDA-231) were obtained from the Lombardi Cancer Center, Georgetown University Medical Center. Cell lines were cultured on polystyrene culture dishes (Corning) and grown in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS). The injectable form (IPS200) of the standardized Ginkgo biloba extract EGB 761® was used. This injectable form is devoid of protocyanidins, which are known to interact with proteins in vitro (Defeuder, 1998 Ullstein Medical). The injectable form of EGB 761® and GKB (BN 52021) isolated from EGB 761® were provided by the Institut Henri Beaufour-IPSEN (Paris, France).
- Radioligand Binding Assays. Cells were scraped from 150 mm culture dishes into 5 ml phosphate buffered saline (PBS), dispersed by trituration, and centrifuged at 500×g for 15 min. Cell pellets were re-suspended in PBS and assayed for protein concentration. [3H]PK 11195 binding studies on 50 μg of protein from cell suspensions were performed as previously described (Papadopoulos, V. et al., 1990, J. Biol. Chem. 265: 3772-3779; Hardwick, M. et al., 1999, Cancer Research, 59: 631-632) the contents of which are incorporated herein by reference. [N-methyl-3H]PK 11195 (1-(2-chlorophenyl)-N-methyl-N-(1-methyl-propyl)-3-isoquinolinecarboxamide; sp. Act. 83.50 (Ci/mmol), was obtained from Du Pont-New England Nuclear (Wilmington, Del.) and PK 11195 was obtained from Research Biochemicals Incorporated (Natick, Mass.). Scatchard plots were analyzed by the LIGAND program (Munson, P J, and Robbard, D. 1980, Anal. Biochem., 107: 220-239) (BIOSOFT, Ferguson, Mo.).
- Protein Measurement. Protein levels were measured by the Bradford method (Bradford, MM, 1976, Anal. Biochem., 72: 248-254) using the Bio-Rad Protein Assay kit (Bio-Rad Laboratories, Hercules, Calif.) with bovine serum albumin as a standard.
- RNA (Northern) Analysis. PBR mRNA expression in MDA-231 cells treated with the various compounds was examined by Northern Blot analysis as we previously described (Hardwick, M., et al., 1999, Cancer Research, 59: 831-842). In brief, total cellular RNA was isolated using the RNAzol B reagent (TEL-TEST, Inc., Friendswood, Tex.) and chloroform. 20 μg of total RNA from each cell line were run on 1% agarose gels and transferred overnight to nylon membranes (S&S Nytran, Schleicher & Schuell, Keene, N.H.) (21). A 0.2 kb human PBR (hPBR) cDNA fragment (derived from the pCMV5-PBR plasmid vector containing the full length hPBR kindly given by Dr. Jerome Strauss, University of Pennsylvania, Pa.) was radiolabeled with [α-32P]dCTP using a random primers DNA labeling system (Life Technologies, Gaithersburg, Md.). The hybridization conditions were as we previously described (Hardwick, M., et al., 1999, Cancer Research, 59: 831-842). Autoradiography was performed by exposing the blots to X-OMAT AR film (Kodak, Rochester, N.Y.) at −70° C. for 4-48 hr. Quantification of PBR mRNA was carried out using the SigmaGel software (Jandel Scientific, San Rafael, Calif.).
- Nucleic Acid Arrays. We used the Atlas human cDNA expression array I from Clontech (Palo Alto, Calif.). This array contains 588 human PCR-amplified cDNA fragments of 200-500 bp long immobilized on a positively charged nylon membrane. MDA-231 cells were treated with and without 20 μg/ml EGB 761® for 48 hours. Poly A+ RNA was isolated from control and EGB 761®-treated cells. 32P-labeled cDNA probes were generated from each poly A+RNA and hybridized to the Atlas array according to the manufacturer's recommendations. Autoradiography was performed by exposing the blots to X-OMAT AR film (Kodak, Rochester, N.Y.) at −70° C. for 4-96 hr. Quantification of the hybridization seen was carried out using the SigmaGel software (Jandel Scientific, San Rafael, Calif.). Multiple exposures were used in order to detect genes expressed at low levels. The three internal controls, ubiquitin, G3PDH and β-actin were used to compare the relative expression levels of the detected gene products in the control and EGB 761®-treated cells. Experimental variations were corrected using the ratios of gene expression versus the internal controls. The effect of the EGB 761® treatment on each gene product is expressed as % of control (untreated) cells. The results presented herein show genes affected consistently, at a level above 30% of control, by the EGB 761® treatment.
- BrdU Cell Proliferation Assays. MDA-231 cells were plated on 96-well plates (Corning, Corning, N.J.) at a concentration of approximately 10,000 cells/well (24 h incubation) or approximately 5,000 cells/well (48 h incubation) in DMEM supplemented with 0.1% FBS. The cells were then incubated in 10% FBS with various concentrations of EGB 761® or GKB for the indicated time periods. Differences in cell proliferation were analyzed by measuring the amount of 5-bromo-2′deoxyuridine (BrdU) incorporation determined by the BrdU ELISA (Boehringer Mannheim, Indianapolis, Ind.). Incorporation of BrdU was measured at 450 nm (reference at 690 nm).
- Analysis of oxidative stress. Levels of cellular oxidative stress were measured using the
fluorescent probe 2,7-dichlorofluorescin diacetate (2,7-DCF; Molecular Probes, Inc., Eugene, Oreg.) as described in Goodman, Y. and Mattson, M. P., Exp. Neurol., 128: 1-12, 1994. In brief, cells were cultured in 96-well plates and treated for 48 hours with the indicated concentrations of EGB 761®. At the end of the treatment the cells were washed and incubated in the presence of 50μM 2,7-DCF in PBS. Fluorescence was then quantified using the Victor2 quantitative detection fluorometer (EGG-Wallac, Inc., Gaithersburg, Md.). - Biological Evaluation In Vivo. The MDA-231 human breast cancer (estrogen insensitive) xenograft model was used for in vivo screening of EGB 761® and GKB. Based on the in vitro data and previously published in vivo data (23) the doses used were 50 mg/kg for the EGB 761® and 1 mg/kg for the GKB. Female athymic nude mice (NCI/Charles River, Frederick, Md.) are injected subcutaneously with 8×106 MDA-231 tumor cells and tumors are allowed to form to a volume of ˜100 to 150 mm3. At this time, groups of 10 animals per compound were injected either orally for the EGB 761® or intraperitoneally for the GKB once a day for a month. Twice weekly tumor sizes and body weights were recorded for all animals for the 30 days of treatment as well for 30 days after the end of the treatment. At that time the animals were sacrificed and the tumors were removed and processed for immunohistochemistry. Animal care was in accordance with institutional guidelines.
- Immunocytochemistry of MDA-231 tumors. MDA-231 tumors removed from the mice treated with or without EGB 761® or GKB were fixed in 10% buffered formalin. Tumors were sectioned and then placed on glass slides and processed as we previously described (19). For immunohistochemistry with anti-PBR primary antibodies, tissue sections were treated with a 30% H2O2/methanol mixture (1:9 ratio) for 5 min at room temperature to neutralize endogenous peroxidase activity and then washed well with PBS. Primary antibody in 10% calf serum in PBS was added to sections at a concentration of 1:500 at RT for 1 h. Secondary antibody reactions were performed using horseradish peroxidase-coupled goat anti-rabbit secondary antibody diluted 1:500 in PBS supplemented with 10% calf serum. After washing the slides three times in PBS for 2 min each, fresh H2O2 diluted 1:1,000 with 3-amino-9-ethyl carbazole (AEC) was added and slides were incubated for 1 h at 37° C. The slides were then rinsed in distilled H2O before mounting with Crystal/Mount.
- Statistical Analysis. Comparison of multiple means was performed with InStat's one-way analysis of variance (ANOVA) (GraphPad Inc., San Diego, Calif.). All F statistics and P values for one-way ANOVAs are provided in the text. Comparison of individual drug treatments to the control treatments was performed with unpaired t-test. All p values for unpaired t-tests are provided in the text.
- Results
- EGB 761® and GKB reduce the PBR Ligand Binding Capacity of the MDA-231 Human Breast Cancer Cells.
FIG. 1 shows that increasing concentrations of the injectable form of EGB 761® inhibit in time-dependent manner the PBR ligand binding capacity (Bmax), determined using saturation isotherms with the radiolabeled ligand PK 11195 followed by Scatchard analysis of the data. Similar results were obtained using isolated GKB (FIG. 2 ). Interestingly, EGB 761® and GKB decreased PBR levels by 66% of control values. No significant effects on the receptor affinity (Kd) could be seen (5.8±1.4 pmol/mg protein, n=12). - EGB 761® and GKB reduce the PBR mRNA Expression in MDA-231 Human Breast Cancer Cells. RNA (Northern) blot analysis was performed in order to determine if the differences seen in PBR ligand binding between the control and the EGB 761®- or GKB-treated cells reflect an effect on PBR mRNA expression. As shown in
FIG. 3 , both EGB 761® and GKB reduced PBR mRNA levels. This result fits with the results presented above on the PBR ligand binding expression. - EGB 761® and GKB Inhibit MDA-231 Cell Proliferation. Using the Bromodeoxyuridine (BrdU) Cell Proliferation ELISA (Boehringer-Mannheim, Indianapolis, Ind.), we examined the effect of increasing concentrations of EGB 761® on MDA-231 cell proliferation.
FIG. 4 shows that EGb-761 inhibits in a concentration- and time-dependent manner the MDA-231 cell proliferation. This effect of EGB 761® was reversible, even for the highest concentration of EGB 761® used. (FIG. 5 ). Incubation of MDA-231 cells for 48 hours with EGB 761®, followed by washing and incubation for another 48 hours in EGB 761®-free medium, resulted in the recovery of the MDA-231 proliferative activity. Increasing concentrations of GKB also inhibited the MDA-231 cell proliferation after 48 hours treatment (FIG. 6 ). - EGB 761® and GKB Do Not Have The Same Level of Inhibition Against MCF-7 Cell Proliferation as They Do Against MDA-231 Cell Proliferation. Compared to the MDA-231 cells, the non-aggressive MCF-7 cells contain extremely low (<60 fold) PBR levels, as determined by both ligand binding studies and mRNA analyses, we examined whether EGB 761® and GKB affect the MCF-7 cell proliferation rate to the same degree as it affects MDA-231 cell proliferation rate.
FIG. 7 clearly shows that neither EGB 761® nor GKB affect MCF-7 cell proliferation to the same degree as they affect the MDA-231 cell proliferation. - EGB 761® Does Not Affect MDA-231 Free Radical Levels. Recent in vivo and in vitro studies demonstrated that the terpene constituents of EGB 761®, including GKB, have anti-oxidant properties. In order to determine whether the anti-proliferative effect of EGB 761® was due to its anti-oxidant properties, we determined the free radical levels in MDA-231 cells treated with and without increasing concentrations of EGB 761® (
FIG. 8 ). Although a 20% decrease in free radical levels could be seen, this effect was neither statistically significant nor dose-dependent, indicating that the effect seen was not due to an EGB 761®-induced decrease of free radical levels in the cells. - EGB 761® Regulates the MDA-231 Transcriptional Program Related to Cell Proliferation. The results presented above indicate that EGB 761® and GKB inhibit PBR expression and cell proliferation in the PBR-rich and highly aggressive MDA-231 breast cancer cells. The non-aggressive MCF-7 cells, which contain extremely low PBR levels, did not respond to EGB 761® treatment to the same degree as that of the MDA-231 breast cancer cells. In order to determine whether the effect of EGB 761® (20 μg/ml for 48 hours) on MDA-231 cells was specific for PBR or whether other genes involved in cell proliferation were affected by the treatment, we used a cDNA array representing 588 distinct human genes. As noted under Materials and Methods, experimental variations were corrected using the ratios of gene expression versus the internal controls. The effect of the EGB 761® treatment on each gene product is expressed as % of control (untreated) cells. Only consistent changes above 30% of control values are presented in
FIG. 9 and Table I. - Biological Evaluation of the Effect of EGB 761® and GKB in Vivo In order to assess the effect of EGB 761® and GKB on tumor cell proliferation and PBR expression in an in vivo setting we used the mammary fat pad xenograft implantation model (See Medina, D., J. Mamm. Gland. Biol. Neopl. 1:5-19, 1996).
FIG. 10 shows that 30 days treatment with either 50 mg/kg EGB 761® or with 1 mg/kg GKB resulted in a 35% (p=0.037) and 32% (p=0.043) decrease in tumor size, measured a month after the end of the treatment, respectively. These treatments did not affect the animal body weight (data not shown). Considering these in vitro data on the effect of EGB 761® and GKB on PBR expression in MDA-231 cells, we examined whether EGB 761® and GKB also decreased PBR expression in the MDA-231 xenografts.FIG. 11 (A-D) shows horseradish peroxidase (HRP) staining of the PBR antiserum used to detect the 18,000 molecular weight protein in MDA-231 xenografts from vehicle-treated animals. The hematoxylin counterstain was omitted in order to distinguish the nuclear localization of PBR (19) in the tumors.FIG. 11A shows the middle of a tumor where the nuclear localization of the 18,000 PBR protein can be easily seen (see arrowheads).FIG. 11B shows the immunostaining seen in the edge of the tumor obtained from vehicle-treated animals. A higher magnification of the immunostaining seen in the edge of the tumor obtained from vehicle-treated animals is shown inFIG. 1C , and a control treated with a non-specific antiserum is shown inFIG. 11D . Treatment with either EGB 761® (FIG. 11E ) or GKB (FIG. 11F ) reduced the nuclear PBR expression present in cells found in the middle of the tumor. Interestingly, treatment with either EGB 761® (FIG. 11G ) or GKB (FIG. 11H ) also eliminated the nuclear PBR expression present in the cells at the edge of the tumors. However, in the later case cytosolic immunostaining could be seen (FIGS. 11G and H). These data were replicated in sections taken from xenografts grown in three separate animals. - It is of interest to note that even in the presence of high concentrations of either EGB 761® or GKB, PBR levels and rates of cell proliferation could not be reduced below 30% of normal values. This suggests that there is a minimum of PBR required to maintain membrane integrity and cell function. It should be also noted that even at the highest concentrations used, neither EGB 761® nor GKB were toxic for the cells, because cell proliferation recovered upon removal of the compounds. These data suggest that these compounds are cytostatic and not cytotoxic. Additional cytotoxicity assays indicated that under the same conditions neither EGB 761® nor GKB induced any significant cell death.
- The absence of any significant decrease in the amount of reactive oxygen species produced in the MDA-231 cells by EGB 761® or GKB suggests that their anti-oxidant properties were not responsible for decreasing PBR expression and cell proliferation in the MDA-231 cells. These results indicate that these compounds may regulate PBR gene transcription either directly or indirectly.
- The finding that EGB 761® and GKB decreased PBR expression and cell proliferation in the highly aggressive, nuclear PBR-expressing MDA-231 cells, but did not affect the non-aggressive MCF-7 cells, which have extremely low PBR levels and are devoid of nuclear PBR, to the same degree as they did for MDA-231 cells, provides an additional support to the hypothesis that the presence of PBR may be a determinant factor for the aggressive phenotype of breast tumor cells. Moreover, this observation further demonstrates the specificity of the effect of EGB 761® and GKB on targeting the regulation of PBR expression. This later finding brought us to two key questions raised by the current study: is the expression of other genes regulated by EGB 761®? is there a transcriptional program activated or inhibited by EGB 761®, where PBR is at the origin or a part of a cascade of events, responsible for altering the proliferation rate of MDA-231 cells? To address these questions, we utilized the Atlas Human cDNA Expression Array. As indicated in Table I, treatment of MDA-231 cells with the EGB 761® extract induced alterations in the transcriptional expression of 36 out of 588 genes examined. Not surprisingly, the vast majority of the affected genes have close ties to either cell proliferation, differentiation, or apoptosis. Perhaps the most telling of the effects EGB 761® has on the MDA-231 cell line is the down-regulation of the p120 proliferation-cell nuclear antigen. p120 is used as a prognostic indicator in breast cancer patients and prostate adenocarcinomas (Perlaky, L., et al., Cancer Res., 52: 428-436, 1992; Zhuang, S. H. et al., Endocrinology, 139: 1197-1207, 1998). More importantly, however, p120 is an immunocytochemical marker of proliferating cells. Down-regulation of this proliferation marker by 68% thus confirms our data demonstrating that EGB 761® inhibits MDA-231 cell proliferation.
- Using a human cDNA expression array we examined the effect of the EGB 761 treatment on the expression of 588 genes in MDA-231 cells. We found that the treatment increased the expression of the c-Myc protooncogene and decreased the expression of 35 gene products, including oncogenes (AP-1, PE-1, RhoA, n-Myc), cell cycle regulators (CDK2, p55CDC, PCNA p120), signal transduction modulators (NET1, ERK2), apoptosis-related products (SGP-2, NIP1) receptors (A2A, RXR-beta, Grb2), transcription factors (Id-2, ATF-4, ETR101, ETR-103), growth factors (HB-EGF, HGF-like), and cell adhesion molecules (CD19, L1CAM, integrins α3, α4, α6, β5, Mac-1, β-catenin) which are directly involved in various pathways regulating cell proliferation. Considering that the compounds tested were effective only on the MDA-231-cells, which express high levels of PBR, these data suggest that the expression of nuclear PBR may be a determining factor for a tumor cell to acquire an aggressive and invasive phenotype.
TABLE I Effect of EGB 761 ® on MDA-231 gene expression examined using the Atlas human cDNA expression array as described under Materials and Methods. Name % Change Function References Oncogenes and Tumor Suppressers c-Myc +75% basic helix-loop-helix-leucine zipper transcription factor (37) Myc/Max heterodimers induce cell-cycle progression, apoptosis, and malignant transformation c-Jun −78% part of the AP-1 transcription factor that regulates genes involved (38) in cell proliferation RhoA −93% GTP-binding protein that is an important regulator of cell (39) proliferation (40) RhoA inactivation inhibits HL60 cell proliferation APC −59% APC mutations are associated with both hereditary and sporadic (41) colorectal cancers (42) a negative post-translational regulator of β-catenin PE-1 −42% transcription factor (43) Cell Cycle Control Proteins Prothymosin-α −79% acidic nuclear protein that is upregulated in proliferating (44) thymocytes, lymphocytes from leukemia patients, and in malignant breast lesions Myeloblastin −66% a serine protease involved in leukemia cell differentiation (45) p55CDC −63% similar to mitosis regulators CDC4 and CDC20 (46) expression positively correlated with cell proliferation status p120 Proliferating-cell −68% nucleolar protein expressed in proliferating cells (47) Nuclear Antigen a prognostic indicator for breast cancer patients and prostate (48) adenocarcinoma CDK2 −83% cyclin-dependent tyrosine kinase involved in progression through (49) the cell cycle cyclin E/Cdk2 inactivates the retinoblastoma tumor suppresser to allow the cell to progress to S phase (50) Vitamin D inhibition of LNCaP cell proliferation coincided with a reduction in Cdk2 activity Intracellular Transducers NET1 −55% RhoA-specific guanine exchange factor (51) NIH3T3-transforming protein ERK2 −46% member of the extracellular signal-related protein kinase family (52) activated upon cell stimulation Apoptosis-Related Proteins Adenosine A2A −40% G protein-coupled receptor involved in the cAMP signaling pathway (53) Receptor Flt3 ligand −58% ligand for the Flt3 cytokine receptor tyrosine kinase (54) induces proliferation of leukemic myeloid cells Grb2 −70% an adapter protein that links receptor tyrosine kinases to the (55) Ras/MAPK signaling pathway via its SH2 domain Clusterin −54% a glycoprotein associated with cell adhesion and apoptosis (56, 57) increased expression is linked to Alzheimer's disease (58) RXR-β −55% retiniod-activated transcription factor (59) inhibition of chondrocyte proliferation by retinoic acid causes a (60) reduction in RXR-β mRNA expression Glutathione S- −39% a multi-drug resistance gene that is overexpressed in various (61, 62) transferase P human tumors (63) chemical inhibition of GST-P inhibits proliferation of Jurkat T cells N-Myc −74% c-myc family member (64) associated with early-onset retinoblastoma TRADD −51% TNFR-associated death domain protein (65) involved in TNFR-induced cell growth and differentiation NIP-1 −40% originally described as a yeast nuclear transport protein (66) part of the translation initiation factor 3 (elF3) core complex (67) DNA-Binding/Transcription Factors Id-2 −65% a member of the Id helix-loop-helix family of transcriptional (68) inhibitors involved in proliferation of human pancreatic cancer cells ATF4 −42% a member of the ATF/CREB family of transcription factors (69) regulates Ras-induced transformation of NIH3T3 cells ETR103 −65% a macrophage-associated immediate early gene (70) ETR101 −60% a lymphocyte-associated immediate early gene (71) Cell Surface Antigens and Adhesion Molecules CD19 B-lymphocyte −62% B-lymphocyte integral membrane protein (72) Antigen expression is down-regulated during retinoid-inhibition of lymphoblastoid B-cell proliferation L1CAM −72% neural cell adhesion molecule (73) increased L1CAM expression is associated with high-grade migration of glioma cells β-catenin −58% involved in cadherin-mediated cell-cell interactions (74) interacts with the TCF/LEF transcription factors in the Wnt signaling pathway Integrin Subunits αM −41% mediates cellular adherence of human neutrophils with LFA-1β (75) α subunit of the elastase receptor β5 −55% β subunit of the vitronectin receptor (VR) (76) involved in cessation of oligodendrocyte proliferation (77) involved in murine retinal angiogenesis (78) α4 −49% cross-linking α4 integrins inhibits LB lymphoma cell proliferation (79) also involved in metastasis of melanoma and lymphoma cells (80) α3 −77% a functionally perturbing α3 integrin antibody inhibits human (81) epithelial cell proliferation α6 −53% overexpression of α6 integrin collaborates with ErbB2 to induce a (82) more malignant phenotype in NIH3T3 cells Extracellular Signaling/Communication Proteins Macrophage Colony- −31% regulates the proliferation, differentiation, and survival of (83) stimulating Factor-1 monocytes, macrophages and their precursors (84) (CSF-1) initiates a mitogenic signal that is required throughout G1 phase CSF-1 stably transfected ovarian granulosa cells exhibit enhanced cell proliferation Heparin-binding EGF- −62% overexpressed in numerous human glioma cell lines and in a (85) like Growth Factor majority of glioblastomas (HB-EGF) stimulates human glioma cell proliferation Hepatocyte Growth −81% a transmembrane protein tyrosine kinase found to be (86) Factor-like Protein overexpressed in hepatoblastoma and in human primary liver (87) (HGFLP) carcinoma induces proliferation and migration of murine keratinocytes Inhibin α −69% a member of the inhibin family of heterodimeric growth factors (88) inhibin α is a marker of trophoblastic neoplasia and is highly (89) expressed in virilizing adenomas - Two members of the Myc family of transcription factors, c-Myc and n-Myc, were found to be grossly altered in this experiment. Expression of the proto-oncogene c-Myc was increased by 75% while expression of n-Myc was reduced by 74%. Both of these genes are overexpressed in several cancer types (Kim, C. J., et al., Virchows Arch., 434: 301-305, 1999; Dang, C. V., Mol. Cel. Biol., 19: 1-11, 1999) and are strongly correlated with tumor cell proliferation. Previous studies have shown that arrest of neuroblastoma cell growth by the tyrosine kinase inhibitor genistein is accompanied by down-regulation of n-Myc expression. This data fits extremely well with our cell proliferation and n-Myc data. Overexpression of c-Myc, however, is associated with a stimulation of cell proliferation in normal serum conditions. Overexpression of c-Myc induces cell death in the absence of serum or other survival factors. Taken together the data implies that deregulation of c-Myc expression requires the altered expression of other genes, as well.
- In our microarray experiment, we discovered the deregulated expression of several other c-Myc-related genes. One such gene, prothymosin α (proT α), is induced by c-Myc. However, expression of proT α is reduced by 79% rather than increased, as might be predicted by up-regulation of c-Myc. Further, expression of other c-Myc target genes such as cdc25A, cyclin A, and cyclin E are unaffected by treatment of MDA-231 cells with EGB 761®, suggesting either a treatment-specific or a cell line-specific short circuit in c-Myc-regulated gene transcription. Other data gathered from the microarray experiment further supports this hypothesis. c-Myc transcriptional regulation is under the control of APC and β-catenin. However, both of these genes are down-regulated by EGB 761® in MDA-231 cells (59 and 58%, respectively) while c-Myc is up-regulated. While some of this data appears to be contradictory, much of the published data on the role of c-Myc in cell proliferation, differentiation, and cell death also appears contradictory.
- Similar to the altered regulation of c-Myc and Myc-related proteins by EGB 761®, the microarray experiment exposed disruption of several signaling molecules. EGB 761® treatment resulted in a 93% reduction in the expression of RhoA, a gene encoding a GTP-binding protein involved in numerous cellular phenomena, and a 55% reduction in NET1 expression, a RhoA-specific guanine exchange factor. Interestingly, RhoA has been demonstrated to regulate cyclin E/Cdk2 activity in fibroblasts. Activation of cyclin E/Cdk2 complex is crucial to the progression of the cell cycle from G1 to S-phase. Regulation of cyclin E/Cdk2 activity has also been demonstrated by c-Myc. Although the significance of these two phenomena is not immediately obvious, it should be noted that expression of Cdk2 is reduced by 83% by EGB 761®.
- Other important signaling molecules are also down-regulated by EGB 761®. Expression of the adapter molecule Grb2 is reduced by 70%. Grb2 plays an important role in cellular signaling by physically linking signal transducers such as receptor tyrosine kinases to the Ras/MAPK pathway. With regard to the MAPK pathway, expression of the MAP/ERK family member ERK2 is down-regulated by 46% and expression of the c-Jun transcription factor is reduced by 78%. Interestingly, it has been reported that EGB 761® is a suppressor of AP-1 transcription factor stimulated by phorbol esters. These data imply that the effects of EGB 761® on MDA-231 cell proliferation are accompanied by a broad reduction in mRNAs with functional relationships with one another.
- Another interesting finding from the microarray experiment is the reduced expression of several integrins. The integrins are a large family of cell-cell and cell-extracellular matrix adhesion receptors that are composed of two transmembrane glycoprotein subunits, one α- and one β-subunit. All of the integrins represented in Table I are involved in the regulation of cell proliferation in some way. For example, integrin αM is part of the elastase receptor. ONO-5046, an elastase inhibitor, suppresses the proliferation of polyoma virus- and Kirsten sarcoma virus-transformed BALB/c3T3 cells and of Capan-1 pancreatic carcinoma cells. Moreover, integrin α4 has been implicated in the accumulation of distal metastases in melanoma, sarcoma, and lymphoma cell models. It is important to emphasize that integrins function as heterodimers of one α- and one β-subunit. Reduced expression of either the α- or the β-subunit is clearly important in the regulation of integrin receptor function.
- The expression of some key growth factor genes, such as the hepatocyte growth factor-like and EGF-like growth factor, were also reduced by EGB 761®. It is possible that the EGB 761®-induced inhibition of cell proliferation may be due to the reduced expression of these growth factors that may act as autocrine regulators of cell growth.
- EGB 761® and GKB are intended to be provided to recipient patient in an amount sufficient to combat cancer in said patient or in an amount sufficient to affect the expression (negatively or positively) of the gene products listed in Table 1, hereinabove. An amount is said to be sufficient to combat cancer if the dosage, route of administration, etc. of the EGB 761® and GKB are sufficient to influence such a response.
- A composition is said to be “pharmacologically acceptable” if its administration can be tolerated by a recipient patient. Such an agent is said to be administered in a “therapeutically effective amount” if the amount administered is physiologically significant. An agent is physiologically significant if its presence results in a detectable change in the physiology of a recipient patient.
- EGB 761® and GKB can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby these materials, or their functional derivatives are optionally combined in admixture with a pharmaceutically acceptable carrier vehicle. Suitable vehicles and their formulation, inclusive of other human proteins, e.g., human serum albumin, are described, for example, in Remington's Pharmaceutical Sciences (16TH ED., Osol, A. ed., Mack Easton Pa. (1980)). In order to form a pharmaceutically acceptable composition suitable for effective administration, such compositions will contain an effective amount of the above-described compounds together with a suitable amount of carrier vehicle.
- Additional pharmaceutical methods may be employed to control the duration of action. Control release preparations may be achieved through the use of polymers to complex or absorb the compounds. The controlled delivery may be exercised by selecting appropriate macromolecules (for example polyesters, polyamino acids, polyvinyl, pyrrolidone, ethylenevinylacetate, methylcellulose, carboxymethylcellulose, or protamine sulfate) and the concentration of macromolecules as well as the method of incorporation in order to control release. Another possible method to control the duration of action by controlled release preparations is to incorporate the compounds of the present invention into particles of a polymeric material such as polyesters, polyamino acids, hydrogels, poly(lactic acid) or ethylene vinylacetate copolymers. Alternatively, instead of incorporating these agents into polymeric particles, it is possible to entrap these materials in microcapsules prepared, for example, interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly (methylmethacrylate) microcapsules, respectively, or in colloidal drug delivery systems, for example, liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences (1980).
- EGB 761® and isolated GKB can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual or topical routes of administration and can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch. Such dosage forms can also comprise, as is normal practice, additional substances other than such inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, the elixirs containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.
- Preparations according to this invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions. Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
- Compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as coca butter or a suppository wax.
- Compositions for nasal or sublingual administration are also prepared with standard excipients well known in the art.
- The dosage of EGB 761® or isolated GKB in the compositions of this invention may be varied; however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained. The selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment. The dose can be administered as a single dose or divided into multiple doses. An effective dose amount of either EGB 761® or isolated GKB depends upon the condition being treated, the route of administration chosen and ultimately will be decided by the attending physician or veterinarian.
-
- 37. Amati, B., Alevizopoulos, K., and Vlach, J. Myc and the Cell Cycle. Frontiers in Bioscience, 3: 250-268, 1998.
- 38. Huang, W. and Erikson, R. L. Signal Transduction. p. 161. Chapman and Hall, 1996.
- 39. Hu, W., Bellone, C. J., and Baldassare, J. J. RhoA stimulates p27(Kip) degradation through its regulation of cyclin E/CDK2 activity. J. Biol. Chem., 274: 3396-3401, 1999.
- 40. Aepfelbacher, M., Essler, M., Luber, D. Q., and Weber, P. C. ADP-ribosylation of the GTP-binding protein RhoA blocks cytoplasmic division in human myelomonocytic cells. Biochem. J., 308: 853-858, 1995.
- 41. Jeanteur, P. The role of APC in colon cancer: Zeroing in on Myc. Bulletin du Cancer (France), 85: 925-928, 1998.
- 42. Munemitsu, S., Albert, I., Souza, B., Rubinfeld, B., and Polakis, P. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc. Natl. Acad. Sci. U.S.A., 92: 3046-3050, 1995.
- 43. Klemsz, M., Hromas, R., Raskind, W., Bruno, E., and Hoffman, R. PE-1, a novel ETS oncogene family member, localizes to chromosome 1q21-q23. Genomics, 20: 291-294, 1994.
- 44. Gomez-Marquez, J., Segade, F., Dosil, M., Pichel, J. G., Bustelo, X. R., and Freire, M. The expression of prothymosin alpha gene in T lymphocytes and leukemic lymphoid cells is tied to lymphocyte proliferation. J. Biol. Chem., 264: 8451-8454, 1989.
- 45. Bories, D., Raynal, M. C., Solomon, D. H., Darzynkiewicz, Z., and Cayre, Y. E. Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell, 59: 959-968, 1989.
- 46. Kao, C. T., Lin, M., O'Shea-Greenfield, A., Weinstein, J., and Sakamoto, K. M. Over-expression of p55Cdc inhibits granulocyte differentiation and accelerates apoptosis in myeloid cells. Oncogene, 13: 1221-1229, 1996.
- 47. Landberg, G. and Roos, G. The Cell Cycle in Breast Cancer. APMIS, 105: 575-589, 1997.
- 48. Perlaky, L., Valdez, B. C., Busch, R. K., Larson, R. G., Jhiang, S. M., Zhang, W. W., Brattain, M., and Busch, H. Increased growth of NIH/3T3 cells by transfection with human p120 complementary DNA and inhibition by a p120 antisense construct. Cancer Res., 52: 428-436, 1992.
- 49. Zhuang, S. H. and Burnstein, K. L. Antiproliferative Effect of 1alpha,25-dihydroxyvitamin D3 in Human Prostate Cancer Cell Line LNCaP Involves Reduction of Cyclin-
dependent Kinase 2 Activity and Persistent G1 Accumulation. Endocrinology, 139: 1197-1207, 1998. - 50. Chan, A. M., Takai, S., Yamada, K., and Miki, T. Isolation of a novel oncogene, NET1, from neuroepithelioma cells by expression cDNA cloning. Oncogene, 12: 1259-1266, 1996.
- 51. Ahn, N. G. and Tolwinski, N. S. U0126: An Inhibitor of MKK/ERK Signal Transduction in Mammalian Cells. Promega Notes, 71: 4-13, 1999.
- 52. Coppee, F., Gerard, A. C., Denef, J. F., Ledent, C., Vassart, G., Dumont, J. E., and Parmentier, M. Early occurrence of metastatic differentiated thyroid carcinomas in transgenic mice expressing the A2a adenosine receptor gene and the human papillomavirus type 16 E7 oncogene. Oncogene, 13: 1471-1482, 1996.
- 53. Dehmel, U., Zaborski, M., Meierhoff, G., Rosnet, O., Birnbaum, D., Ludwig, W. D., Quentmeier, H., and Drexler, H. G. Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells. Leukemia, 10: 261-270, 1996.
- 54. Benito, M., Valverde, A. M., and Lorenzo, M. IGF-I: a mitogen also involved in differentiation processes in mammalian cells. Int. J. Biochem. Cell Biol., 28: 499-510, 1996.
- 55. Chevalier, R. L. Effects of ureteral obstruction on renal growth. Semin. Nephrol., 15: 353-360, 1995.
- 56. Truong, L. D., Sheikh-Hamad, D., Chakraborty, S., and Suki, W. N. Cell Apoptosis and Proliferation in Obstructive Uropathy. Semin. Nephrol., 18: 641-651, 1998.
- 57. Choi-Miura, N. H. and Oda, T. Relationship between multifunctional protein “clusterin” and Alzheimer disease. Neurobiol. Aging, 17: 717-722, 1996.
- 58. Lotan, R. Retinoids and chemoprevention of aerodigestive tract cancers. Cancer Metastasis Rev., 16: 349-356, 1997.
- 59. Hagiwara, H., Inoue, A., Nakajo, S., Nakaya, K., Kojima, S., and Hirose, S. Inhibition of proliferation of chondrocytes by specific receptors in response to retinoids. Biochem. Biophys. Res. Commun., 222: 220-224, 1996.
- 60. Campos, L., Oriol, P., Sabido, O., and Guyotat, D. Simultaneous expression of P-glycoprotein and BCL-2 in acute myeloid leukemia blast cells. Leuk. Lymphoma., 27: 119-125, 1997.
- 61. Lacave, R., Coulet, F., Ricci, S., Touboul, E., Flahault, A., Rateau, J. G., Cesari, D., Lefranc, J. P., and Bernaudin, J. F. Comparative evaluation by semiquantitative reverse transcriptase polymerase chain reaction of MDR1, MRP and GSTp gene expression in breast carcinomas. Br. J. Cancer, 77: 694-702, 1998.
- 62. McCaughan, F. M., Brown, A. L., and Harrison, D. J. The effect of inhibition of glutathione S-transferase P on the growth of the Jurkat human T cell line. J. Pathol., 172: 357-362, 1994.
- 63. Kim, C. J., Chi, J. G., Choi, H. S., Shin, H. Y., Ahn, H. S., Yoo, Y. S., and Chang, K. Y. Proliferation not Apoptosis as a Prognostic Indicator in Retinoblastoma. Virchows Arch., 434: 301-305, 1999.
- 64. Newton, K., Harris, A. W., Bath, M. L., Smith, K. C., and Strasser, A. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J., 17: 706-718, 1998.
- 65. Gu, Z., Moerschell, R. P., Sherman, F., and Goldfarb, D. S. NIP1, a gene required for nuclear transport in yeast. Proc. Natl. Acad. Sci. U.S.A., 89: 10355-10359, 1992.
- 66. Phan, L., Zhang, X., Asano, K., Anderson, J., Vornlocher, H. P., Greenberg, J. R., Qin, J., and Hinnebusch, A. G. Identification of a translation initiation factor 3 (elF3) core complex, conserved in yeast and mammals, that interacts with elF5. Mol. Cell Biol., 18: 4935-4946, 1998.
- 67. Kleeff, J., Ishiwata, T., Friess, H., Buchler, M. W., Israel, M. A., and Korc, M. The helix-loop-helix protein Id2 is overexpressed in human pancreatic cancer. Cancer Res., 58: 3769-3772, 1998.
- 68. Mielnicki, L. M., Hughes, R. G., Chevray, P. M., and Pruitt, S. C. Mutated Atf4 suppresses c-Ha-ras oncogene transcript levels and cellular transformation in NIH3T3 fibroblasts. Biochem. Biophys. Res. Commun., 228: 586-595, 1996.
- 69. Shimizu, N., Ohta, M., Fujiwara, C., Sagara, J., Mochizuki, N., Oda, T., and Utiyama, H. A gene coding for a zinc finger protein is induced during 12-O-tetradecanoylphorbol-13-acetate-stimulated HL-60 cell differentiation. J. Biochem. (Tokyo.), 111: 272-277, 1992.
- 70. Shimizu, N., Ohta, M., Fujiwara, C., Sagara, J., Mochizuki, N., Oda, T., and Utiyama, H. Expression of a novel immediate early gene during 12-O-tetradecanoylphorbol-13-acetate-induced macrophagic differentiation of HL-60 cells. J. Biol. Chem., 266: 12157-12161, 1991.
- 71. Dolcetti, R., Zancai, P., Cariati, R., and Boiocchi, M. In vitro effects of retinoids on the proliferation and differentiation features of Epstein-Barr virus-immortalized B lymphocytes. Leuk. Lymphoma, 29: 269-281, 1998.
- 72. Tsuzuki, T., Izumoto, S., Ohnishi, T., Hiraga, S., Arita, N., and Hayakawa, T. Neural cell adhesion molecule L1 in gliomas: correlation with TGF-beta and p53. J. Clin. Pathol., 51: 13-17, 1998.
- 73. Young, C. S., Kitamura, M., Hardy, S., and Kitajewski, J. Wnt-1 induces growth, cytosolic beta-catenin, and Tcf/Lef transcriptional activation in Rat-1 fibroblasts. Mol Cell Biol., 18: 2474-2485, 1998.
- 74. Cai, T. Q. and Wright, S. D. Human leukocyte elastase is an endogenous ligand for the integrin CR3 (CD11b/CD18, Mac-1, alpha M beta 2) and modulates polymorphonuclear leukocyte adhesion. J. Exp. Med, 184: 1213-1223, 1996.
- 75. De Deyne, P. G., O'Neill, A., Resneck, W. G., Dmytrenko, G. M., Pumplin, D. W., and Bloch, R. J. The Vitronectin Receptor Associates with Clathrin-coated Membrane Domains Via the Cytoplasmic Domain of its beta5 Subunit. J. Cell Sci., 111: 2729-2740, 1998.
- 76. Milner, R. and Ffrench-Constant, C. A developmental analysis of oligodendroglial integrins in primary cells: changes in alpha v-associated beta subunits during differentiation. Development, 120: 3497-3506, 1994.
- 77. Friedlander, M., Theesfeld, C. L., Sugita, M., Fruttiger, M., Thomas, M. A., Chang, S., and Cheresh, D. A. Involvement of integrins
alpha v beta 3 andalpha v beta 5 in ocular neovascular diseases. Proc. Natl. Acad. Sci. U.S.A., 93: 9764-9769, 1996. - 78. Bittner, M., Gosslar, U., Luz, A., and Holzmann, B. Sequence Motifs in the Integrin alpha4 Cytoplasmic Tail Required for Regulation of In Vivo Expansion of Murine Lymphoma Cells. J. Immunol., 161: 5978-5986, 1998.
- 79. Holzmann, B., Gosslar, U., and Bittner,
M. alpha 4 integrins and tumor metastasis. Curr. Top. Microbiol. Immunol., 231: 125-141, 1998. - 80. Gonzales, M., Haan, K., Baker, S. E., Fitchmun, M., Todorov, I., Weitzman, S., and Jones, J. C. A Cell Signal Pathway Involving Laminin-5, alpha3beta1 Integrin, and Mitogen-activated Protein Kinase can Regulate Epithelial Cell Proliferation. Mol. Biol. Cell, 10: 259-270, 1999.
- 81. Falcioni, R., Antonini, A., Nistico, P., Di, S. S., Crescenzi, M., Natali, P. G., and Sacchi,
A. Alpha 6beta 4 andalpha 6beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. Exp. Cell Res., 236: 76-85, 1997. - 82. Roussel, M. F. Regulation of cell cycle entry and G1 progression by CSF-1. Mol. Reprod. Dev., 46: 11-18, 1997.
- 83. Keshava, N., Gubba, S., and Tekmal, R. R. Overexpression of Macrophage Colony-stimulating Factor (CSF-1) and its Receptor, c-fms, in Normal Ovarian Granulosa Cells Leads to Cell Proliferation and Tumorigenesis. J. Soc. Gynecol. Investig., 6: 41-49, 1999.
- 84. Mishima, K., Higashiyama, S., Asai, A., Yamaoka, K., Nagashima, Y., Taniguchi, N., Kitanaka, C., Kirino, T., and Kuchino, Y. Heparin-binding Epidermal Growth Factor-like Growth Factor Stimulates Mitogenic Signaling and is Highly Expressed in Human Malignant Gliomas. Acta Neuropathologica, 96: 322-328, 1998.
- 85. Zhu, M. and Paddock, G. V. Expression of the Hepatocyte Growth Factor-like Protein Gene in Human Hepatocellular Carcinoma and Interleukin-6-induced Increased Expression in Hepatoma Cells. Biochim. Biophys. Acta, 1449: 63-72, 1999.
- 86. Wang, M. H., Dlugosz, A. A., Sun, Y., Suda, T., Skeel, A., and Leonard, E. J. Macrophage-stimulating protein induces proliferation and migration of murine keratinocytes. Exp. Cell Res., 226: 39-46, 1996.
- 87. Pelkey, T. J., Frierson, H. F., Mills, S. E., and Stoler, M. H. Detection of the alpha-subunit of Inhibin in Trophoblastic Neoplasia. Hum. Pathol., 30: 26-31, 1999.
- 88. Arola, J., Liu, J., Heikkila, P., Voutilainen, R., and Kahri, A. Expression of inhibin alpha in the human adrenal gland and adrenocortical tumors. Endocrine Res., 24: 865-867, 1998.
- 89. Kallakury, B. S., Sheehan, C. E., Rhee, S. J., Fisher, H. G., Kaufman, R. P. J., Rifkin, M. D., and Ross, J. S. The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: A comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34(cdc2). Cancer, 85: 1569-1576, 1999.
- The contents of the publications and patents referenced herein are incorporated herein by reference in their entirety.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/405,392 US20060182821A1 (en) | 1999-08-12 | 2006-04-17 | Use of a plant extract |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14860499P | 1999-08-12 | 1999-08-12 | |
PCT/US2000/022174 WO2001012208A1 (en) | 1999-08-12 | 2000-08-11 | Use of ginkgo extract |
US10/018,448 US7078434B1 (en) | 1999-08-12 | 2000-08-11 | Use of Ginkgo extract |
US11/405,392 US20060182821A1 (en) | 1999-08-12 | 2006-04-17 | Use of a plant extract |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/018,448 Continuation US7078434B1 (en) | 1999-08-12 | 2000-08-11 | Use of Ginkgo extract |
PCT/US2000/022174 Continuation WO2001012208A1 (en) | 1999-08-12 | 2000-08-11 | Use of ginkgo extract |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060182821A1 true US20060182821A1 (en) | 2006-08-17 |
Family
ID=36659081
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/018,448 Expired - Fee Related US7078434B1 (en) | 1999-08-12 | 2000-08-11 | Use of Ginkgo extract |
US11/405,392 Abandoned US20060182821A1 (en) | 1999-08-12 | 2006-04-17 | Use of a plant extract |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/018,448 Expired - Fee Related US7078434B1 (en) | 1999-08-12 | 2000-08-11 | Use of Ginkgo extract |
Country Status (1)
Country | Link |
---|---|
US (2) | US7078434B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080254126A1 (en) * | 2006-04-07 | 2008-10-16 | Shinji Shimada | Composition comprising nanoparticle ginkgo biloba extract with the effect of brain function activation |
CN105561309A (en) * | 2014-10-30 | 2016-05-11 | 成都百裕科技制药有限公司 | Pharmaceutical composition containing ginkgolide B and thrombin inhibitor and preparation method and application of pharmaceutical composition |
CN116251095A (en) * | 2023-04-21 | 2023-06-13 | 南京力诚生物医药科技有限公司 | Application of bilobalide B in preparing medicine for preventing tumor metastasis |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070128212A1 (en) * | 2003-11-28 | 2007-06-07 | Mutsumi Sano | Ceramidase inhibitor |
US8426567B2 (en) * | 2005-08-26 | 2013-04-23 | Econugenics, Inc. | Method for enhancing mammalian immunological function |
ITTO20100538A1 (en) * | 2010-06-23 | 2011-12-23 | Alessandro Quattrone | SCREENING PROCEDURE OF COMPOUNDS FOR THE TREATMENT OF TUMORS WHICH CARRY ON ACTIVE ONCOGENS AND RELATIVE COMPOUNDS |
CN113817738B (en) * | 2021-10-20 | 2023-06-16 | 湖南科技学院 | Ginkgo long-chain non-coding RNA and application thereof in ginkgolide biosynthesis |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4734280A (en) * | 1984-07-19 | 1988-03-29 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Treatment or prevention of PAF Acether-induced maladies |
US5002965A (en) * | 1989-05-09 | 1991-03-26 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Use of ginkgolides to prevent reperfusion injury in organ transplantation |
US5346894A (en) * | 1991-11-04 | 1994-09-13 | Ruth Korth | Treatment of lyso PAF-mediated diseases with PAF antagonists and procedure for determining their efficacy |
US5541183A (en) * | 1993-12-31 | 1996-07-30 | Sunkyong Industries Co., Ltd. | Ginkgolide derivatives |
US6274621B1 (en) * | 1995-11-09 | 2001-08-14 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Ginkgolides for inhibition of membrane expression of benzodiazepine receptors |
US6316690B1 (en) * | 1999-08-04 | 2001-11-13 | Tosk, Inc. | Non-mammalian transgenic animal model for cellular proliferative diseases |
US20030157095A1 (en) * | 1998-03-25 | 2003-08-21 | Vassilios Papadopoulos | Peripheral-type benzodiazepine receptor: a tool for detection, diagnosis, prognosis, and treatment of cancer |
US20040053857A1 (en) * | 2002-07-01 | 2004-03-18 | Solbec Pharmaceuticals Limited | Glycoalkaloid compositions and various uses thereof |
US20050003031A1 (en) * | 1997-08-19 | 2005-01-06 | Aylward James Harrison | Anti-cancer compounds |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3832056A1 (en) | 1988-09-21 | 1990-03-22 | Scholle Helmut Dr Med | USE OF A GINKGO EXTRACT |
DE4008868A1 (en) | 1990-03-20 | 1991-09-26 | Schaut Mikrofilm App | Duplicator for microfilm cameras - is formed as tube with camera box lens connecting, end an built-in lens system |
DE4208868A1 (en) | 1992-03-04 | 1993-09-09 | Michaelis Peter Dr Med | Use of ginkgolide cpds., esp. ginkgolide B - in treatment of metastatic cancers, to enhance the effect of chemotherapeutic agents |
-
2000
- 2000-08-11 US US10/018,448 patent/US7078434B1/en not_active Expired - Fee Related
-
2006
- 2006-04-17 US US11/405,392 patent/US20060182821A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4734280A (en) * | 1984-07-19 | 1988-03-29 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Treatment or prevention of PAF Acether-induced maladies |
US5002965A (en) * | 1989-05-09 | 1991-03-26 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Use of ginkgolides to prevent reperfusion injury in organ transplantation |
US5346894A (en) * | 1991-11-04 | 1994-09-13 | Ruth Korth | Treatment of lyso PAF-mediated diseases with PAF antagonists and procedure for determining their efficacy |
US5541183A (en) * | 1993-12-31 | 1996-07-30 | Sunkyong Industries Co., Ltd. | Ginkgolide derivatives |
US6274621B1 (en) * | 1995-11-09 | 2001-08-14 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Ginkgolides for inhibition of membrane expression of benzodiazepine receptors |
US20050003031A1 (en) * | 1997-08-19 | 2005-01-06 | Aylward James Harrison | Anti-cancer compounds |
US20030157095A1 (en) * | 1998-03-25 | 2003-08-21 | Vassilios Papadopoulos | Peripheral-type benzodiazepine receptor: a tool for detection, diagnosis, prognosis, and treatment of cancer |
US6316690B1 (en) * | 1999-08-04 | 2001-11-13 | Tosk, Inc. | Non-mammalian transgenic animal model for cellular proliferative diseases |
US20040053857A1 (en) * | 2002-07-01 | 2004-03-18 | Solbec Pharmaceuticals Limited | Glycoalkaloid compositions and various uses thereof |
US20050227928A1 (en) * | 2002-07-01 | 2005-10-13 | Solbec Pharmaceuticals Limited | Glycoalkaloid compositions and various uses thereof |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080254126A1 (en) * | 2006-04-07 | 2008-10-16 | Shinji Shimada | Composition comprising nanoparticle ginkgo biloba extract with the effect of brain function activation |
US8105637B2 (en) * | 2006-04-07 | 2012-01-31 | Shinji Shimada | Composition comprising nanoparticle Ginkgo biloba extract with the effect of brain function activation |
CN105561309A (en) * | 2014-10-30 | 2016-05-11 | 成都百裕科技制药有限公司 | Pharmaceutical composition containing ginkgolide B and thrombin inhibitor and preparation method and application of pharmaceutical composition |
CN116251095A (en) * | 2023-04-21 | 2023-06-13 | 南京力诚生物医药科技有限公司 | Application of bilobalide B in preparing medicine for preventing tumor metastasis |
Also Published As
Publication number | Publication date |
---|---|
US7078434B1 (en) | 2006-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Marín‐Aguilar et al. | NLRP3 inflammasome suppression improves longevity and prevents cardiac aging in male mice | |
US20060182821A1 (en) | Use of a plant extract | |
Bernsdorf et al. | Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial | |
JP2007126472A (en) | Use of ginkgo extract | |
Bemis et al. | Anti-prostate cancer activity of a β-carboline alkaloid enriched extract from Rauwolfia vomitoria | |
Columbano et al. | Gadd45β is induced through a CAR‐dependent, TNF‐independent pathway in murine liver hyperplasia | |
Hernández‐Vargas et al. | Transcriptional profiling of MCF7 breast cancer cells in response to 5‐Fluorouracil: Relationship with cell cycle changes and apoptosis, and identification of novel targets of p53 | |
Nimmanapalli et al. | Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells | |
Börner et al. | Comparative analysis of mu-opioid receptor expression in immune and neuronal cells | |
Wirth et al. | Spinal muscular atrophy and therapeutic prospects | |
WO2000062076A1 (en) | Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma | |
Kiang et al. | Regulation of heat shock protein 72 kDa and 90 kDa in human breast cancer MDA-MB-231 cells | |
Akane et al. | Downregulation of immediate-early genes linking to suppression of neuronal plasticity in rats after 28-day exposure to glycidol | |
Sun et al. | Protective effects of nicotine against glutamate-induced neurotoxicity in PC12 cells | |
EP1865319A1 (en) | Method of testing whether a tumor is susceptible to treatment with a ginkgo biloba extract or Ginkgolide B by testing whether the cancer is characterized by an over-expression of peripheral-type benzodiazepine receptor protein | |
CZ2002247A3 (en) | A medicament for preventing or reducing foam cell development or removing foam cells, further preventing or treating a vascular disease, for treating or preventing cancer or Alzheimer?s disease, PPAR delta activity inhibitor, pharmaceutical preparation and method of identifying a compound and the compound per se. | |
Song et al. | Monitoring the gene expression profiles of doxorubicin-resistant acute myelocytic leukemia cells by DNA microarray analysis | |
Höpfner et al. | Meta‐iodobenzylguanidine induces growth inhibition and apoptosis of neuroendocrine gastrointestinal tumor cells | |
US8227434B1 (en) | Materials and methods for treating oncological disorders | |
Zhu et al. | Cholinergic Regulation of Morphine Release from Human White Blood Cells: Evidence for a Novel Nicotinic Receptor via Pharmacological and Micro Array Analysis | |
AU2001247832B2 (en) | Method of profiling a plant extract | |
KR102615053B1 (en) | A biomarker for diagnosing BCR-ABL-independent tyrosine kinase inhibitor resistance comprising FAM167A and a composition for preventing or treating chronic myeloid leukemia targeting FAM167A | |
US20030211456A1 (en) | Method of profiling a plant extract | |
US20070196352A1 (en) | Vegf-induced genes and their therapeutic use | |
JP2009232705A (en) | Method for discriminating glioma origin and glioma therapeutic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SOCIETE DE CONSEILS DE RECHERCHES ET D' APPLICATIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DRIEU, KATY;REEL/FRAME:017992/0196 Effective date: 20060606 Owner name: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DRIEU, KATY;REEL/FRAME:017992/0196 Effective date: 20060606 |
|
AS | Assignment |
Owner name: GEORGETOWN UNIVERSITY, DISTRICT OF COLUMBIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PAPADOPOULOS, VASSILIOS;REEL/FRAME:019572/0443 Effective date: 20060606 |
|
AS | Assignment |
Owner name: IPSEN PHARMA S.A.S., FRANCE Free format text: CHANGE OF NAME;ASSIGNOR:SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.);REEL/FRAME:023034/0251 Effective date: 20081128 Owner name: IPSEN PHARMA S.A.S.,FRANCE Free format text: CHANGE OF NAME;ASSIGNOR:SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.);REEL/FRAME:023034/0251 Effective date: 20081128 Owner name: IPSEN PHARMA S.A.S., FRANCE Free format text: CHANGE OF ADDRESS;ASSIGNOR:IPSEN PHARMA S.A.S.;REEL/FRAME:023034/0378 Effective date: 20080918 Owner name: IPSEN PHARMA S.A.S.,FRANCE Free format text: CHANGE OF ADDRESS;ASSIGNOR:IPSEN PHARMA S.A.S.;REEL/FRAME:023034/0378 Effective date: 20080918 |
|
XAS | Not any more in us assignment database |
Free format text: CHANGE OF ADDRESS;ASSIGNOR:IPSEN PHARMA S.A.S.;REEL/FRAME:023034/0378 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: IPSEN PHARMA S.A.S., FRANCE Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ADDRESS PREVIOUSLY RECORDED ON REEL 023034 FRAME 0251. ASSIGNOR(S) HEREBY CONFIRMS THE ADDRESS SHOULD BE 65 QUAI GEORGES GORSE, 92100 BOULOGNE-BILLANCOURT, FRANCE;ASSIGNOR:SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.);REEL/FRAME:029636/0777 Effective date: 20081128 |
|
AS | Assignment |
Owner name: IPSEN PHARMA S.A.S., FRANCE Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME PREVIOUSLY RECORDED ON REEL 296336 FRAME 0777. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S.;REEL/FRAME:037430/0194 Effective date: 20081128 |